Official Symbol: TP53provided by HGNC
Official Full Name: tumor protein p53provided by HGNC
Primary Source: HGNC:11998
See related: Ensembl:ENSG00000141510; HPRD:01859; MIM:191170
Gene type: protein coding
RefSeq status: REVIEWED
Organism: Homo sapiens
Lineage: Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; Homo
Also known as: p53; LFS1; TRP53; FLJ92943; TP53
Summary: This gene encodes tumor protein p53, which responds to diverse cellular stresses to regulate target genes that induce cell cycle arrest, apoptosis, senescence, DNA repair, or changes in metabolism. p53 protein is expressed at low level in normal cells and at a high level in a variety of transformed cell lines, where it's believed to contribute to transformation and malignancy. p53 is a DNA-binding protein containing transcription activation, DNA-binding, and oligomerization domains. It is postulated to bind to a p53-binding site and activate expression of downstream genes that inhibit growth and/or invasion, and thus function as a tumor suppressor. Mutants of p53 that frequently occur in a number of different human cancers fail to bind the consensus DNA binding site, and hence cause the loss of tumor suppressor activity. Alterations of this gene occur not only as somatic mutations in human malignancies, but also as germline mutations in some cancer-prone families with Li-Fraumeni syndrome. Multiple p53 variants due to alternative promoters and multiple alternative splicing have been found. These variants encode distinct isoforms, which can regulate p53 transcriptional activity. [provided by RefSeq]

[Top][Help]Genomic regions, transcripts, and products

(minus strand) Go to reference sequence details Try our new Sequence Viewer

[Top][Help]Bibliography

GeneRIFs: Gene References Into Function What's a GeneRIF?

	1.	There are two polymorphic points in the 7th intron of human p53 gene, which could be associated with genetic susceptibility of oral neoplasms.
	2.	ZBTB2 is a potential proto-oncogenic master control gene of the p53 pathway and, in particular, is a potent transcription repressor of the cell cycle arrest gene p21 by inhibiting p53 and Sp1
	3.	Alemtuzumab is effective irrespective of genetic high-risk subgroups with TP53 mutations.
	4.	P53 expression seems to be related to some histopathological features of basal cell carcinomas
	5.	The arginine variant of rs1042522 within p53 is associated with increased risk of primary open-angle glaucoma.
	6.	analysis of the transcriptional axis mutant p53, E2F1 and ID4 which promotes tumor neo-angiogenesis
	7.	p53 staining was highest in Bowen's disease followed by actinic keratosis, squamous cell carcinoma, Paget's disease, keratoacanthoma, basal cell carcinoma and normal skin
	8.	There was no evidence that TP53 Arg72Pro or MDM2 309T>G, either singly or in combination, influence breast cancer risk in BRCA1 or BRCA2 mutation carriers.
	9.	Studied Neuroblastoma tumors from patients for miR-34a expression levels, 1p status, mutations in the TP53 coding region and mutations of the TP53 binding site. No mutations were identified in the coding region of TP53, or in the TP53 binding site.
	10.	A family with LFS harbors a germline TP53 mutation (R248W) located in the functional domain of the protein that binds to the minor groove of the DNA.
	11.	The increased levels of p53 in post-selection human mammary epithelial cells are due to the presence of an Mdm2 fragment that binds p53 but does not result in its degradation.
	12.	Results suggest that ribavirin enhances activities of mTOR and p53, which may account for its antiviral and antitumor effects.
	13.	Results suggest that alteration of the substrate specificity via binding to Mdmx may contribute to efficient ubiquitination and inactivation of p53 by Mdm2.
	14.	Data show that neither the status of p53 (wild-type vs. mutated, or inhibited by pifithrin-alpha) nor the expression of O(6)-methylguanine-DNA methyltransferase significantly affected the cell response to temozolomide.
	15.	Both Forkhead Transcription Factor 3a and Tumor Suppressor Protein p53 gene expression change under various stresses, leading to diverse physiological functions.
	16.	The higher frequency of the Pro/Pro phenotype of p53 in African American patients with colorectal adenocarcinoma is associated with an increased incidence of p53 mutations, with advanced tumor stage, and with short survival.
	17.	Data show that absolute alcohol as a fixative produced the best immunohistochemical staining of p53.
	18.	Presence of S100A6 coincides with more efficient nuclear accumulation of p53 under stress conditions.
	19.	Data show that Cav-1 expression in tumor tissues was correlated with both the Ki-67 and p53 expression.
	20.	TP53 deletion and chromosome 17 aneusomy is a common event in gastric adenocarcinoma and other TP53 alterations, as mutation, may be implicated in the distinct carcinogenesis process of diffuse and intestinal types.
	21.	Data show that DADS induces G(2)/M arrest in colon cancer SW480 cells, probably through the downregulation of PCNA, p53 and cyclin B1 and upregulation of p21(WAF1).
	22.	Results suggest that an increased transcription of pro-apoptotic genes (p53 and Bcl-x(S)) in eutopic endometrium is significantly associated with endometriosis, which indicates dysregulation of apoptotic gene transcription associated with disease.
	23.	Data show that wt-p53 can suppress excessive replication of centrosomes that may contribute to the upregulation of Gadd45a and BubR1 protein expression as well as the downregulation of Aurora A protein expression.
	24.	the molecular mechanisms of different oxidizing molecules in inducing survival or the apoptotic response by activating Nrf2 or p53 in adenocarcinoma cells
	25.	The structure of the wild-type p53 protein and the structural & functional data that provide the molecular basis for understanding the effects of common cancer mutations are presesnted. Review.
	26.	depletion of Sestrin2 or Dram failed to affect autophagy in p53-deficient cells
	27.	Sirt1 inhibition resulted in an increase in senescence in PC3-p53 cells whereas it resulted in an increase in apoptosis in PC3 cells
	28.	Li-Fraumeni and Li-Fraumeni-like syndrome mutations in p53 are associated with exonic methylation and splicing regulatory elements.
	29.	A genetic predisposition such as the p53 mutation should be investigated in bilateral choroid plexus papillomas in particular
	30.	The median survival time was shorter in patients with tumor TF mRNA levels above median values and when TP53 was mutated.
	31.	significant interrelationships of the investigated molecular alterations and clinicopathological characteristics in diffuse gliomas, which support a promising role of molecular markers (MGMT, p53, Ki-67)in the diagnostic assessment of these neoplasms
	32.	Higher levels of ATP5a1 expression are associated with certain Single Nucleotide Polymorphisms and with TP53 mutation.
	33.	p53 overexpression, NF-kappaB positivity, and beta-catenin loss were predictive factors of adverse clinical outcomes in appendiceal mucinous adenocarcinomas.
	34.	Gambogic acid induced human breast cancer cells MCF-7 apoptosis by reducing bcl-2 expression via p53.
	35.	p53-mediated repression of miR-17-92 expression likely has an important function in hypoxia-induced apoptosis
	36.	The present study shows that the serum level of p53 is lower in the patients with type 2 diabetes than in controls or in subjects with IGT.
	37.	p53(+)bcl-2(-) phenotype is significantly correlated with the basal cell-like subtype and may be associated with the biologic aggressiveness of this cohort of molecular breast cancer.
	38.	there is an an association between HCV core and HAX-1, which promotes 5-FU mediated p53-dependent caspase-7 activation and hepatocyte growth inhibition
	39.	Our data show the first valid clinical evidence of the deregulation of HIC1-SIRT1-p53 loop in lung tumorigenesis and prognosis
	40.	we provided evidence for a crucial role for direct inhibition of p53 by MDM2 and suppression of the p19(ARF)/p53 axis in neuroblastoma tumorigenesis
	41.	NF-kappaB promotes oridonin-induced apoptotic and autophagic cell death through regulating p53 activation in HT1080 cells.
	42.	status of p53 (wild-type versus mutant) rather than expression level of p53, MDM2, or p14(ARF) is likely to be the more critical determinant of clinical outcome in esophageal squamous cell carcinoma.
	43.	Results correlate with altered p53 phosphorylation and target gene expression in untreated human tumor samples and show that HIF2alpha likely contributes to tumor cell survival including during radiation therapy.
	44.	disruption of ERalpha-p53 interaction in vivo resulting in restoration of functional p53 is a cellular response to radiation
	45.	The clearer definition of the transcriptional behavior of p53 interaction with its RE will provide better insight toward the understanding of its fundamental role in cellular networks.
	46.	analysis of the interaction between the transactivation domain of p53 and PC4
	47.	Findings suggest that p53beta might play an important role in the formation of renal cell carcinoma and it might be used as a new predictor and therapeutic target for RCC.
	48.	The results of particular polymorphisms analyses were not highly significant after correction for multiple comparisons, present data suggest that variation at the p53 and p73 gene may have a role in Alzheimer's disease occurrence.
	49.	TP53 polymorphism has an age-dependent role n PAI-1 regulation
	50.	Stochastic modeling and simulation of the p53-MDM2/MDMX loop.
	51.	TP53 codon 72 polymorphisms may be a risk factor for Nasopharyngeal carcinoma (NPC). Homozygote Pro/Pro genotype could significantly increase susceptibility to NPC, whereas Arg allele markedly decreases NPC risk.
	52.	In a high-risk Venezuela population, Arg carriers had a 4.6-fold higher risk of gastric cancer. The Arg/Arg genotype was more frequent in poorly differentiated gastric adenocarcinomas & the Arg/Pro genotype in well/moderately differentiated cases.
	53.	inhibition of glycolysis may only be beneficial for radiation therapy of cancer expressing wild-type p53.
	54.	Results demonstrated that the inhibition of spontaneous B cell apoptosis by CpG DNA was correlated to up-regulation of Bcl-xL, IAP and down-regulation of p53 and caspase 3 mediated through PI3K/AKT signaling.
	55.	The slow oligomerization of free p53, competing with spontaneous denaturation, has implications for the possible regulation of p53 by binding proteins and DNA that affect tetramerization kinetics as well as equilibria.
	56.	Forodesine induces apoptosis of CLL cells bypassing the DNA-damage/ATM/p53 pathway.
	57.	SIK1 links LKB1 to p53-dependent anoikis and suppresses metastasis.
	58.	The acetylation of Lys-120 does not appear to regulate the ability of p53 to interact with the pro-apoptotic proteins BCL-XL and BAK. However, displacement of the inhibitory MCL-1 protein from BAK is compromised when Lys-120 acetylation is blocked.
	59.	Data show that kidney bean husk extract exhibited antitumor effects accompanied by the increase in p-AMPK and p-Acc as well as antitumor proteins p53 and p21.
	60.	Data show that phloretin inhibits cell proliferation via the induction of apoptosis through the activation of p53, JNK and p38 mitogen-activated protein kinase signaling.
	61.	Data show that the inhibition of cell proliferation with L.lac CF was associated with an increase in p53 and p21 expression, the reduction of cyclin D1 expression, and retinoblastoma protein phosphorylation.
	62.	Results suggest that the electrophilic carbon center located in the alpha,beta-unsaturated carbonyl moiety of the cyclopentenone ring might be critical for the control of DNA-binding activity as well as cellular levels of p53 by 15d-PGJ(2).
	63.	Results suggest that lack of correlations between TGF-beta1 and p53 proteins could indicate mutations at the TGF-beta1-dependent apoptotic pathway.
	64.	Results show that no striking relationship was found in expression patterns of p53, Bcl-2, caspase-3, and Fas.
	65.	miR-34a contributes to megakaryocytic differentiation of K562 cells independently of p53.
	66.	Impaired p53 binding to importin: a novel mechanism of cytoplasmic sequestration identified in oxaliplatin-resistant cells.
	67.	Consistent with in vitro findings, a strong correlation between beta(4) overexpression and HIPK2 inactivation by cytoplasmic relocalization was observed in wtp53-expressing breast carcinomas.
	68.	Cabin1 inhibits p53 function on chromatin in the quiescent state; the presence of inactive p53 on some promoters might allow a prompt response upon DNA damage.
	69.	Mutations in the p53 gene impair its tumor suppressor function. Several of these tumor-derived p53 mutants can confer further aggressive oncogenic properties when overexpressed in p53-null cells.
	70.	Polymorphisms in p53 codon 72 and MDM2 SNP309 may be implicated in breast cancer of young women.
	71.	Data show that it can function in an autoregulatory loop consisting of RAP80, HDM2, and the p53 master regulatory network, implpying an important role for this loop in genome stability and oncogenesis.
	72.	The human p53 isoforms Delta133p53 and p53beta function in an endogenous regulatory mechanism for p53-mediated replicative senescence.
	73.	Axin is a critical determinant in p53-dependent tumour suppression in which Pirh2 and Tip60 have different roles in triggering cell-cycle arrest or apoptosis depending on the severity of genotoxic stress.
	74.	Findings confirmed the relationship of p53, MDM2, and COX-2 with the biological process of pancreatic cancer.
	75.	review of literature analysing influence of radon exposure on mutations TP53 in lung cancer patients; results are not consistent in order to support existence of a radon hotspot in TP53 gene [review]
	76.	The functional relationship of the the ubiquitin-proteasome system (UPS) and the autophagy-lysosomal pathway (ALP) and the interactional role of p53 in vitro, was studied.
	77.	Pirh2 ubiquitin ligase has two novel isoforms that negatively regulate p53 independent of RING finger domains
	78.	ATM and ATR kinases, but not DNA-PK, which participate in DNA damage-activated checkpoints, regulate the phosphorylation of p53 at serine 15 in response to MNNG cell treatment
	79.	Analysis of pair wise genotype combinations revealed increase in risk for specific p73-MDM2 and p73-p53 genotype combinations.
	80.	A method developed to predict the effects of mutations in the p53 cancer suppressor gene, a protein that is involved in over 50% of all human cancers.
	81.	RREB-1 participates in modulating p53 transcription in response to DNA damage
	82.	Findings suggest that the influence of NAT2 genotype, alone or in combination with p53 genotype, may confer increased susceptibility to lung cancer.
	83.	functional inactivation of p53 by COX-2 can be one of the mechanisms by which COX-2 promotes tumorigenesis
	84.	hCLCA2 Is a p53-Inducible Inhibitor of Breast Cancer Cell Proliferation.
	85.	study found no link between polymorphisms in APOE, p53, and p21 genes and primary open-angle glaucoma in Turkish patients,although a larger sample is required to elucidate the role of these polymorphisms in the pathogenesis and course of glaucoma
	86.	Testing for p53 polymorphisms may allow identification of gastric cancer patients who will benefit from oxaliplatin-based adjuvant chemotherapy
	87.	Results show correlation between induction of p53, reactive oxygen species and phospho-p38, whereas p38(MAPK) inhibition rescued cell growth markedly.
	88.	Data demonstrate a novel function of the evolutionarily conserved chromatin remodeling subunit BRG1, which cooperates with CBP to constrain p53 activity and permit cancer cell proliferation.
	89.	p53 was an essential factor for Sp1 overexpression-induced apoptotic cell death in transforming cells.
	90.	This retrospective study evaluated 15 cases of inflammatory myofibroblastic tumours (IMTs) to determine histological atypicality, clinicopathological features, outcomes, and expression of anaplastic lymphoma kinase-1 (ALK1) and p53.
	91.	Epigenetic inactivation of MGMT plays an important role in the survival of glioblastoma patients and this inactivated gene is involved in p53 mutation.
	92.	an interaction between MDM2 SNP 309 and p53 with respect to tumor behaviors (including disease onset, tumor differentiation, LNECS and disease-free survival) was observed in sporadic Taiwanese OSCCs.
	93.	Studies discovered a novel molecular network between p53, KLF4 and ERalpha.
	94.	findings suggest that Stat3 and p53 are cooperatively involved in the development of renal cell carcinoma (RCC) but assessment of their mRNA expression may not be useful for predicting the prognosis of patients with RCC
	95.	Observational study of gene-disease association and DATA ERROR. (HuGE Navigator)
	96.	p53 mRNA expression of chronic benzene poisoning workers or benzene-exposure workers was significantly lower than that of nonexposure workers
	97.	XEDAR as a putative colorectal tumor suppressor that mediates p53-regulated anoikis pathway.
	98.	GPR87 knockdown sensitized cancer cells to DNA damage-induced growth suppression via enhanced p53 stabilization and activation.
	99.	cAMP levels may influence p53 function in malignant cells that retain wt p53, potentially affecting p53 both as a tumor suppressor during cancer initiation and maintenance, and as an effector of the apoptotic response to DNA-damaging agents
	100.	PAS may represent a novel class of drug that induces apoptosis in CLL cells independently of p53 status by a mechanism involving Noxa up-regulation.
	101.	No association was found between cervical cancer and TP53 codon 72 polymorphism
	102.	Expression of p53, BCL-2 and Ki-67 was upregulated in clinically localized prostate cancer compared with benign prostate tissue, with no alteration in E-cadherin expression.
	103.	Plk1 modulates Topors activity in suppressing p53 function
	104.	Positive expression of p16, Ki-67, and ProEx C and negative expression of p53 seem to be related to HPV-16 infection
	105.	results indicate that LOH of the PTEN gene and of D12S1051 is the molecular pathogenesis of the gastric adenocarcinoma, and the mutation of the TP53 gene is an additional hit for the oncogenesis of choriocarcinoma arising from gastric adenocarcinoma
	106.	incidence of TP53 mutations in pleomorphic xanthoastrocytoma may be underestimated and that molecular approaches should be used for greater diagnostic precision
	107.	When the p53 and MDM2 polymorphisms were combined, no multiplicative joint effect between the MDM2 GG and p53 Pro/Pro genotypes exists in the risk of developing AML
	108.	study investigated whether TP53 codon 72 polymorphism is associated with somatic mutations in breast cancer tumors
	109.	we determined the methylation statuso f the promoter in putative modifier genes: BRCA1, BRCA2, ATM, ATR and P53 in Jewish BRCA1/BRCA2 mutation carriers with or without breast cancer. hypermethylation was detected only in the BRCA1 promotor
	110.	it is proposed that the loss of a second allele of Tp53 leading to the loss of p21 expression, and subsequent cell proliferation, compose a sequence of events that lead to morphological transformation & instigation of ovarian epithelial tumor development
	111.	p53 induces cell apoptosis and inhibits cell migration in part by downregulating TFF2 expression through an AP-1-like site, suggesting that TFF2 may be an important downstream target of p53.
	112.	There were no significant differences in the genotype (P = 0.0927) or allele frequencies (P = 0.1430) for p53 Arg72Pro polymorphism in patients with endometriosis.
	113.	The TP53 expression values obtained by amplicon densitometry and qRT-PCR were significantly and consistently better after automated homogenization (p<0.005) for both uvula and tumor samples.
	114.	The pathway is accelerated in the absence of p53, indicating that p53 normally holds the p16(Ink4a) response.
	115.	A panel of tests for p53 codon 72 Pro/Pro, PAI-1 4G/4G and VEGF -1154A/A may be useful to identify women at risk for implantation failure after IVF-ET.
	116.	Immunohistochemistry detected inhibin-alpha, -betaA and -betaB, Ki67, p53 and glycodelin A in invasive trophoblastic mole.
	117.	Depletion of the outer kinetochore protein hBub1 upon activation of SAC primarily triggers early cell death mediated by p53.
	118.	p53 affects the speed of oocyte development and may influence the oocyte selection through apoptosis during meiotic prophase I
	119.	The frequency of TP53 mutations in low-grade and high-grade carcinoma groups were found in 20% and 70.6%, respectively.
	120.	DN-R175H mutant p53 exerts a gain of oncogenic function by promoting disruption of E-cadherin intercellular contacts and activation of proliferation signals.
	121.	regulation of p53 multimerization that requires the concerted action of JNK and Ubc13 on polysome-bound p53.
	122.	in p53-deficient settings, suppression of ATM sensitizes tumors to DNA-damaging chemotherapy, whereas, in the presence of functional p53, suppression of ATM or its downstream target Chk2 actually protects tumors from being killed by genotoxic agents
	123.	P53 physically interacts with hBub1 at kinetochores in response to mitotic spindle damage suggesting a direct role for hBub1 in the suppression of p53 mediated cell death.
	124.	p53 plays a critical role in synergistic growth inhibition by erlotinib & EGCG via inhibiting nuclear factor-kappaB signaling pathway.
	125.	median pancreatic cancer survival in p53 positive group was 10.0+/-2.2 months and in p53 negative group was 6.0+/-2.5 months
	126.	TRAIL-induced apoptosis by Notch1 signaling is dependent upon p53 up-regulation
	127.	HER-2/neu, and p53 do not seem to play a significant role in the process of high grade transformation of AciCC
	128.	Both p53 and VEGF expression were associated with Microvessel count in gastric carconoma
	129.	cases of resistance to chemotherapy in CLL with TP53 mutation in the absence of the deletion of 17p [review]
	130.	down regulation of miR-34a, miR-29 and miR-17-5p in aggressive CLL with TP53 abnormalities
	131.	Increased p53 expression in the malignant transformation of Barrett's esophagus is accompanied by an upward shift of the proliferative compartment.
	132.	No apparent correlation was found between p12(DOC-1) and p53 expressions in gastric carcinoma.
	133.	Binding to a consensus DNA sequence enhances p53 stability and prevents the formation of the misfolded conformation.
	134.	advanced DSB repair analysis may serve as a novel assay for the functional classification of p53 mutations.
	135.	Enhanced S100A4 protein expression is clinicopathologically significant to metastatic potential and p53 dysfunction in colorectal cancer.
	136.	Combination of p53 expression and p21 loss has an independent prognostic impact on sporadic colorectal cancer.
	137.	Co-depletion of Cdc6 and p53 in normal cells restored Cdk2 activation and Rb phosphorylation, permitting them to enter S phase with a reduced rate of replication.
	138.	p53 mutation present in nonneoplastic mucosa of inflammatory bowel disease patients
	139.	results demonstrate that the TP53-R337H mutation can significantly increase the risk of breast cancer in carriers, which likely depends on additional cooperating genetic factors
	140.	p53 codon 72 polymorphism may serve as a susceptible factor affecting the chances of Recurrent pregnancy loss and Recurrent implantation failure
	141.	Novel germline p53 mutation is associated with glioblastoma and colon cancer.
	142.	These observations suggest that the interaction of HBV and p53 at the levels of protein-protein and DNA-protein, which resulted in inactivation of p53 transactivation.
	143.	Covalent modification of mutant p53 per se is sufficient to induce apoptosis in tumor cells
	144.	Control of p53's transcriptional activity is crucial for determining which p53 response is activated (Review)
	145.	Study provides evidence supporting the association of MDM2 SNP309 with high-grade osteosarcoma risk in females and shows that TP53 Arg72Pro has a prognostic value for overall survival and EFS in osteosarcoma patients.
	146.	Data indicate that MKRN1 is a novel modulator of p53 and p21, preferentially leading cells to p53-dependent apoptosis by suppressing p21.
	147.	p53 nuclear expression is associated with disease progression from intramedullary to extramedullary sites in multiple myeloma.
	148.	Epstein-Barr virus nuclear antigen 3C, one of the EBV latent antigens essential for the B-cell immortalization in vitro, interacts directly with p53
	149.	a central tumour suppressor, p53, enhances the post-transcriptional maturation of several miRNAs with growth-suppressive function, including miR-16-1, miR-143 and miR-145, in response to DNA damage
	150.	epigenetic silencing of the TP53 promoter is not a frequent cause of the disorder in families suggestive of Li-Fraumeni syndrome but with no germline mutations in the coding part of the gene
	151.	The data suggest that dephosphorylation of serine 376 on constitutive nuclear p53 is a sensitive and early signaling event in the response of cells to DNA damage induced by ionizing radiation.
	152.	p53 may play a role in influencing tumor metastasis through Lasp1 in hepatocellular caarcinoma.
	153.	Results indicate that 249(Ser) mutation is a HCC important factor of carcinogenesis in Brazil and it is associated to large and poorly differentiated tumors.
	154.	p53 dysfunction in HCC can cause an upregulation of the HBx protein level through the stabilizing of HBx protein in HCC.
	155.	Data show that with MAK3 knockdown, p53 is stabilized and phosphorylated and there is a significant transcriptional activation of proapoptotic genes downstream of p53, and that localization of Arl8b is altered, suggesting that Arl8b is a Mak3 substrate.
	156.	Results describe the expression pattern of p53, BCL-2 and epidermal growth factor receptor proteins in the hydatidiform moles.
	157.	p53 and ATF-2 partly mediate the overexpression of COX-2 in H(2)O (2)-induced premature senescence of human fibroblasts.
	158.	Our results show that the combination of rAd-p53 and BAI was well tolerated in patients with NSCLC and may have improved the quality of life and delayed the disease progression.
	159.	Inhibition of de novo purine synthesis in human prostate cells results in ATP depletion, AMPK and p53 activation, and induces senescence.
	160.	GATA-1 and p53 interact in erythroid cells, and activation of p53-responsive promoters in an erythroid cell line can be inhibited by the overexpression of GATA-1.
	161.	p53 hot spots, proximal and distal colon tumors were more similar to each other than distal colon and rectal tumors
	162.	UVA-induced apoptosis is caused by extensive oxidative damage leading to p53-regulated mitochondrial release, whereas UVB induces DNA damage and apoptosis signaling upstream of lysosomal membrane permeabilization
	163.	analysis of functional TP53 in nasopharyngeal carcinoma
	164.	gain-of-function p53 mutant acquires the de novo ability to stimulate Gal-3 expression and to increase chemoresistance in anaplastic thyroid carcinomas
	165.	TP53 Arg72Pro associated with the increased risk of sporadic papillary thyroid carcinoma.
	166.	The majority of the cases of Adenosquamous carcinoma of the pancreas had strong nuclear p53 positivity
	167.	Gastric cancer patients who had low FBXW7 expression levels and p53 mutation had a distinctively poor prognosis in comparison with other subgroups.
	168.	describes a third abnormal response pattern characterized by failure of p21 protein accumulation despite a normal p53 protein response
	169.	JFK promotes p53 turnover through assembly of an SCF (Skp1-Cul1-F-box) complex, revealing a pathway for the control of p53 degradation and providing a link between the SCF complex and p53 regulation.
	170.	results also provide a plausible explanation for the evolutionary positive selection of some alleles in the p53 pathway and demonstrate the alleles in the p53 pathway as a good example of antagonistic pleiotropy
	171.	Results suggest that prevalent haplotypes within the TP53 gene may modulate CRC risks in the population.
	172.	None of the inverted papillomas exhibited mutations in TP53
	173.	Suggest a synergistic effect between smoking and TP53 genetic polymorphisms on lung cancer risk compared with each risk factor alone.
	174.	p53 regulates angiogenesis in low-grade astrocytomas
	175.	Increased risk of head and neck cancer among individuals with combined p73 exon 2 G4A and p53 intron 3 variant alleles and a protective effect for those carrying the p53 exon 4-p53 intron 6 diplotype combination.
	176.	Results indicate that wtp53 and p53 mutants may differentially control cancer invasion and metastasis through the p53-MDM2-Slug pathway.
	177.	both NOLC1 and tumor protein 53 work together synergistically to activate the MDM2 promoter in NPC cells.
	178.	the deregulated miR expression pattern, miR-34a, miR-29 and miR-17-5p, in CLL patients with deleted and/or mutated p53 gene are closely associated to the biological subtypes of CLL
	179.	difference in p53 expression between mild and severe levels of photoaging was not statistically significant
	180.	The effects of specific p53 phosphorylations on its interaction with the Taz2 domain of p300, are examined.
	181.	p53 alterations were more frequent in non-endometrioid adenocarcinomas and mixed endometrioid adenocarcinomas-non-endometrioid adenocarcinomas than in high-grade endometrioid adenocarcinomas or low-grade endometrioid adenocarcinomas.
	182.	In the context of mutant p53, PML enhances its cancer-promoting activities.
	183.	MDM2 acts as an ubiquitin E3 ligase, downstream of p53, to regulate the degradation of mammalian FOXO factors.
	184.	NORE1A activates p21(CIP1) via promoting p53 nuclear localization.
	185.	simultaneous phosphorylation of S15 and S20 is causally associated with apoptosis, resulting in increased expression of specific p53-responsive pro-apoptotic genes.
	186.	Data show that FAT10 and mutant p53 levels in gastric cancer tissue were significantly correlated with lymph node metastasis and tumor, nodes, metastasis staging.
	187.	Results suggest that adenovirus-mediated transduction of p53 and p21-specific microRNAs may be useful for gene therapy of human cancers.
	188.	ASPP2 primarily binds to the core domain of p53, whereas iASPP predominantly interacts with a linker region adjacent to the core domain.
	189.	Modulation of the oligomerization state of p53 by differential binding of proteins of the S100 family to p53 monomers and tetramers.
	190.	Genetic changes in TP53 can be detected also in non-neoplastic lesions linked to chronic hepatitis C virus infection.
	191.	WTH3 played an important role in MDR development and revealed one of its transcription regulatory mechanisms, DNA methylation, which antagonized p53's positive impact on WTH3 expression
	192.	The frequency of GST-P polymorphism was not associated with p53 protein accumulation in esophagus epithelium
	193.	Increased metallothionein and p53 expression is associated with oral squamous cell carcinoma.
	194.	A poorer survival was observed among carriers of the variant allele of p53 intron 6 if compared with those carrying both wild-type alleles
	195.	Results identify PLA2R (phospholipase A2 receptor) as a potential new tumour suppressor gene crucial in the induction of cellular senescence through the activation of the p53 pathway.
	196.	acetylation at Lys-120 of p53 negatively regulates a signaling pathway leading to NFAT activation
	197.	ARNTL, RBCK1 and TNIP1 regulate p53 function.
	198.	Crystal structures of two complexes, a p53-like mutant peptide with the N-terminal domains of Mdm2 and Mdmx, respectively, are presented.
	199.	p53 mutations are frequent in tumor-surrounding histologically normal tissue, and some of them might be involved in lung carcinogenesis
	200.	Tubulin acetylation stimulates the binding and the signaling function of transcription factor p53.
	201.	p53 inactivation may promote malignant transformation of a subpopulation of melanocytes with the ability to survive BRAF(V600E)-induced senescence
	202.	11 TP53 SNPs were evaluated in women with CIN3+, 380 with HPV persistance. 3 were associated with increased risk: rs12951053, rs1042522, rs1642785.
	203.	p53-mediated tumor suppression can be attributed at least in part to the biological functions of PKR induced by p53 in genotoxic conditions
	204.	current understanding on p53 ubiquitination by Mdm2 with a particular focus on how the balance between protein levels and other post-translational modifications will direct the p53 response (Review)
	205.	Results indicate that Wip1 up-regulation is important in the pathogenesis of p53(+) and ER(+) breast cancer through the inactivation of p53 by dephosphorylation and the amplification of subsequent estrogenic effects through the E(2)-ERalpha-Wip1 pathway.
	206.	p53 gene mutations apparently precede the morphological changes in affected endometrial cells.
	207.	Artemis and DNA-PKcs participate in a new, signaling pathway to modulate p53 function in response to oxidative stress produced by mitochondrial respiration.
	208.	Data indicate that the level of HCCR-1 in breast cancer tissues is correlated with the HER2 overexpression, p53 mutation, and ER/PR status, and determination of HCCR-1 levels as options for HER2 testing is promising although it needs further evaluation.
	209.	HCC containing R249S can occur in the absence of significant recent exposure to aflatoxins. Short oligonucleotide mass analysis in low ongoing aflatoxin exposure may allow the detection of R249S in plasma several months ahead of clinical diagnosis.
	210.	p53 Arg72Pro Pro/Pro was associated with esophageal cancers.
	211.	Lung adenocarcinoma occurring in young patients tends to have a poorer prognosis, and angiogenesis of lung adenocarcinoma in young patients is more closely correlated with p53 expression than in elderly patients.
	212.	single nucleotide polymorphisms in TP53 gene is associated with lower response rate to the combination chemotherapy in advanced gastric cancer.
	213.	The presence of deleterious TP53 mutations in most, if not all, BRCA1-related breast cancers suggests that p53 loss of function is essential for BRCA1-associated tumorigenesis.
	214.	Study concludes p53 polymorphisms are not associated with primary open angle glaucoma (POAG) in the Japanese population.
	215.	A smaller-sized Sfp53 orthologue shows highly conserved native structure with DNA-binding, N-terminus and C-terminus domains, and has analogous p53 transcriptional activity.
	216.	The N-terminal region of GSK3 beta binds p53, this association promotes the acetylation of p53, and subsequently acetylated p53 dissociates from GSK3.
	217.	model that describes the influence that DNA damage has on the implementation of both the G2/M phase cell cycle arrest and the intrinsic apoptosis induction via its activation of the p53 synthesis process
	218.	Data show that p53 regulates ER expression through transcriptional control of the ER promoter, accounting for their concordant expression in human breast cancer.
	219.	ALK signaling leads to the functional inactivation and/or degradation of p53 in JNK and MDM2 dependent manners.
	220.	In the absence of telomerase, transgenic p53 mice aged with the same kinetics and pathological spectrum as p53 wild type mice.
	221.	There was no clear evidence of case heterogeneity by P53 overexpression except for suggestive differences in the risk association of non-cardia gastric adenocarcinoma in relation to smoking and BMI.
	222.	functional link between Cyr61 and p53 in cancers
	223.	Change of mitochondrial DNA is a common event in colorectal cancer with p53 mutation.
	224.	p53 acetylation liberates BAX from Ku70
	225.	p53 is primarily protective against ultraviolet rays-induced apoptosis in primary human fibroblasts and this activity of p53 does not require DDB2.
	226.	IFI16 and NM23/NDPK are simultaneously bound in vivo to the promoters of the oncogene cMYC and of P53
	227.	a novel mechanism by which mutant p53 acquires its gain of function via transactivating the GRO1 gene in cancer cells.
	228.	An approximately 32-fold increase in caspase-1 expression was observed in the p53-knockin cell line after dengue virus infection.
	229.	Stabilization and activation of p53 by spindle disruption requires the spindle checkpoint kinase TTK/hMps1.
	230.	No relationship was found between p53 mutations and the occurrence of second primary head and neck carcinomas
	231.	Induction of p53 contributes to apoptosis of HCT-116 human colon cancer cells induced by the dietary compound fisetin.
	232.	Cutaneous hidradenocarcinoma has a relatively low frequency of TP53 mutations despite a high rate of p53 protein expression at the immunohistochemical level.
	233.	findings revealed Apak to be a negative regulator of p53-mediated apoptosis
	234.	p53 normally suppresses the generation of tetraploid cells, presumably by activating the intrinsic pathway of apoptosis.
	235.	Data show that FGFR1 and DDHD2 at 8p12 cooperated functionally with MYC, whereas CCND1 and ZNF703 cooperated with a dominant negative form of TP53.
	236.	In leukoblasts from 82 patients with acute myeloid leukemia, various extent and frequency of differential allelic expression in the CDA, DCK, NT5C2, NT5C3, and TP53 genes was observed.
	237.	Results suggest that a physiological level of TopBP1 is essential for normal G(1)/S transition, but a pathological level of TopBP1 in cancer may perturb p53 function and contribute to an aggressive tumor behavior.
	238.	Among the 112 patients with urothelial carcinoma of the upper urinary tract 32 (28.6%) had altered expression of p53
	239.	study examined the associations between p53 mutations, p53 functional status, and mRNA and protein levels in hematopoietic cell lines
	240.	Hepatitis C virus genotype IV and p53 protein levels may have a role in the development of hepatocellular carcinoma among Egyptian patients
	241.	a higher frequency of p53 genetic mutations and increased AgNOR values exist in squamous cell carcinoma compared with basal cell carcinoma and squamous cell papilloma
	242.	We suggest that TP53 Pro47Ser and Arg72Pro polymorphisms and DNA hypermethylation are involved in susceptibility for developing extra-axial brain tumors.
	243.	We concluded that the p53 codon 72 Arg/Pro polymorphism is not associated with Primary open angle glaucoma in Brazilian patients.
	244.	Variants in the TP53 gene may modify the risk of late skin toxicity after radiotherapy.
	245.	Results highlight the role of SMAR1 in masking the active phosphorylation site of p53, enabling the deacetylation of p53 by HDAC1-MDM2 complex, thereby regulating the p53 transcriptional response during stress rescue.
	246.	Data show that upregulation of the p53 tumor suppressor during the restricted period of embryonic development significantly contributes to the Bst phenotype in Rpl24-deficient mice.
	247.	Results establish a new role for H2AX in the p53/p21 pathway and indicate that H2AX is required for p21-induced cell cycle arrest after replication stalling.
	248.	Crystal Structures of Human MdmX (HdmX) in Complex with p53 Peptide Analogues Reveal Surprising Conformational Changes.
	249.	Study provides evidence that p53, binding with Snail, is exported from a K-Ras-mutated cell through a vesicle transport-like mechanism, independently using a p53-nuclear-exporting mechanism.
	250.	This is the first description of p53 signatures adjacent to carcinoma, suggesting a role for this entity in the genesis of serous malignancy
	251.	Internalization of a peptide fragment derived from p53 tumor suppressor protein in human SJSA-1 cancer cells is shown to occur via adsorption-mediated, energy-dependent pathways, resulting in accumulation of the material in endocytic vesicles.
	252.	Data indicates that demethylation of the survivin promoter by decitabine results in p53-dependent survivin repression and that p53 binding can be inhibited by DNA methylation.
	253.	p53 is required for etoposide-induced apoptosis of hESC and reveals, at least in part, the molecular mechanism of DNA-damage-induced apoptosis in hESC
	254.	The Pro allele at codon 72 of p53 was a risk factor for developing lung cancer.
	255.	The binding interactions between the N-terminal transactivation domain (TAD) of p53, the TAZ1, TAZ2, KIX, and nuclear receptor coactivator binding domains of CBP, and the p53-binding domain of HDM2, are examined.
	256.	first report showing p53 overexpression and its genetic background in malignant mixed Mullerian tumors of the peritoneum
	257.	The studies unravel a molecular mechanism underlying sumoylation-regulated p53 function and further uncover a new role of acetylation in antagonizing the inhibitory effect of sumoylation on p53 binding to DNA.
	258.	P53 gene mutations are significantly correlated with p53 protein over-expression in adenocarcinoma of gastric cancer patients from India.
	259.	Over-expression of the Tp53, CCND1, and C-myc genes appears to play a role in development of human cancer by regulating the expression of mRNA.
	260.	p53-dependent apoptosis upregulated by the I143T/G384A mutant PS1 gene may be associated, at least in part, with intracellular Abeta and proteasome impairment
	261.	p53 Pro72 variant is associated with an increased risk for colorectal cancer in the Korean population.
	262.	Hypoxia regulates human lung fibroblast proliferation via p53-dependent and -independent pathways.
	263.	The authors conclude that CinS and ExpR act to increase PlyB levels, thereby influencing the bacterial surface.
	264.	Human papillomavirus-infected esophageal squamous papillomas show low expression of cell-cycle markers (p16, p53).
	265.	Transcriptome profiling and TP53 sequencing of concurrent small cell and prostatic adenocarcinoma to determine the relationship between these entities.
	266.	Report role of p53 in the induction of cyclooxygenase-2 by cisplatin or paclitaxel in non-small cell lung cancer cell lines.
	267.	A recombinant cell-permeable p53 fusion protein is selectively stabilized under hypoxia and inhibits tumor cell growth.
	268.	TP53 genotyping may be of clinical interest in selecting patients who may benefit from cetuximab-based chemotherapy in metastatic colorectal cancer.
	269.	JNK activation essential for the autophagic cell death resulted in upregulation of Beclin-1 expression, Bcl-2 phosphorylation, and p53 phosphorylation, suggesting that these pro-autophagic signaling pathways are involved in the autophagic cell death.
	270.	cDNA microarray analysis does not indicate any specific target or treatment effects of head and neck squamous cell carcinoma with mutant P53 and over-expressed EGFR.
	271.	The efficient degradation of RNA containing AU-rich sequences (ARE) correlates with the efficient binding of p53 to ARE RNA in cytoplasm
	272.	Zalypsis provoked DNA double-strand breaks (DSBs), evidenced by an increase in phospho-histone-H2AX and phospho-CHK2, followed by a striking overexpression of p53 in p53 wild-type cell lines
	273.	increased level of p53 in astrogliomas is increasing as the tumor grade is increasing
	274.	This large study provides statistical evidence for a small increase in risk of ovarian cancer associated with common variants in the TP53 region.
	275.	Results show that p53 abrogation rescues both the small size phenotype and restitutes the functionality of epidermal stem cells of telomerase-deficient mice with dysfunctional telomeres.
	276.	Interferon-gamma induces cellular senescence through p53-dependent DNA damage signaling in human endothelial cells.
	277.	Results reveal a novel and direct role for p14ARF in the p53-independent maintenance of genomic stability.
	278.	p53 deletion without multiple aberrations is an independent negative prognostic factor for disease-free survival, relapse risk, and overall survival
	279.	The integration of PTEN and p53 into a common pathway for the induction of another tumor suppressor, Maspin, constitutes a tumor suppressor network of PTEN/p53/Mapsin that is operational under limited oxygen conditions.
	280.	p53 is not involved in the HDAC4 repression of p21(WAF1/Cip1) expression in cancer cells.
	281.	p53 plays an important role in proliferation in our studied population, since it is overexpressed in 92% of T-cell lymphoma cases.
	282.	The specific knockdown of individual protein kinases (PKs) has enabled the identification of a number of new PKs that control the expression of PCNA and p53 in ovarian cells.
	283.	TBX2 is a cell type-dependent survival factor under a p53-negative background.
	284.	The results of our study do not support a relevant role of the p53 polymorphism in head and neck carcinogenesis, either taken alone or in association with the HPV status.
	285.	EBNA3C enhances the intrinsic ubiquitin ligase activity of Mdm2 toward p53, which in turn facilitated p53 ubiquitination and degradation
	286.	combined deletion of p53 and Pten in bladder epithelium leads to invasive cancer in a novel mouse model. Inactivation of p53 and PTEN promotes tumorigenesis in human bladder cells and is correlated with poor survival in human tumors.
	287.	p53 activation may downregulate the AKT/mTOR pathway through a mechanism involving AMP kinase in mantle cell lymphoma
	288.	glioblastoma patients with TP53 codon 72 Arg/Pro alleles showed significantly shorter survival than those with Arg/Arg alleles
	289.	The over-expression of P53 in Nasal NK/T-cell lymphoma is probably associated with high incidence of EBV infection and unlikely a regulatory protein for the expression of MRP and LRP
	290.	there was no association between CTLA-4 (cytotoxic T-lymphocyte-associated protein 4 ) and p53 gene polymorphisms and gestational trophoblastic diseases
	291.	Relationship of immunohistochemistry scores of altered p53 protein expression in relation to patient's habits and histological grades and stages of squamous cell carcinoma.
	292.	Thermodynamic experiments revealed the importance of hydrophobic interactions in the complex of Taz2 with p53 phosphorylated at Ser(15) and Thr(18).
	293.	Repression of E6 and E7 oncogenes results in restoration of p53 suppressor pathways and induced apoptosis in HPV16-positive oropharyngeal squamous cell cancer cell lines.
	294.	p53 mutation is an early genetic event affecting a diversity of molecular pathways in pancreatic carcinogenesis
	295.	Mutations in TP53 is associated with Salivary Gland Neoplasms.
	296.	Her-2/neu (47.1%), p-53 (31.74%), and their combined expression (15.87%) were not related to grade or stage of tumor in osteosarcoma
	297.	Unlike other DNA damage response-inducing agents, RITA treatment of cells induced a p53-dependent increase in phosphorylation of the eif2 alpha, requiring PKR-like endoplasmic reticulum kinase activity, and led to the downregulation of HIF-1alpha
	298.	The genetic polymorphisms of the p53, genes were found to be significantly different (p<0.05) between the uremic and non-uremic diabetes group
	299.	The release of PCAF from hSirT1 repression favors the assembly of transcriptionally active PCAF/E2F1 complexes onto the P1p73 promoter and p53-independent apoptosis.
	300.	There is a tight association between cold winter temperature and p53 Arg72 and between low UV intensity and MDM2 SNP309 G/G in a cohort of 4029 individuals across Eastern Asia that suggests causative selection.
	301.	Ubiquitination of mammalian AP endonuclease (APE1) regulated by the p53-MDM2 signaling pathway.
	302.	the pathways regulated by the NF1 and p53 tumor-suppressor proteins often cooperate in the development of ovarian carcinomas with serous differentiation
	303.	The prevalence of COX2 and p53 risk-alleles contributes towards susceptibility to the disease.
	304.	miR-125b, a brain-enriched microRNA, is a bona fide negative regulator of p53 in both zebrafish and humans
	305.	CCR5 and p53 codon 72 gene polymorphisms: implications in breast cancer development
	306.	p53 oligomerization precedes its acetylation by providing docking sites for acetyltransferases.
	307.	p53 is selectively stabilized because the unanchored polyubiquitin that accumulates after USP5 knockdown is able to compete with ubiquitinated p53 but not with Mdm2 for proteasomal recognition
	308.	p53 either alone or associated with Human papilloma virus was not associated with the presence of uterine cervix adenocarcinoma
	309.	Study shows that TGFbeta-dependent cell migration, invasion and metastasis are empowered by mutant-p53 and opposed by p63.
	310.	Data suggest that the activation of the p53 pathway is involved in suberoyl bis-hydroxamic acid-induced apoptosis in MCF-7 cells.
	311.	Results suggest that nm23-H1 may act as a cellular protector against oxidative stress, possibly triggering increased expression of GPX1 and the p53-related antioxidative pathway.
	312.	CARF may act as a novel key regulator of the p53 pathway at multiple checkpoints
	313.	These findings deciphered the structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX.
	314.	These results suggest that multiple TP53 mutations in glioblastomas are due to deficient repair of DNA double-strand breaks caused by mutational inactivation of the NBS1 gene.
	315.	p53 stabilisation and caspase-3 activation concur to determine the apoptotic response mediated by Apollon knockdown in breast cancer cells.
	316.	Increased p53 expression in luminal cells was related to focal infiltration of polymorphonuclear leucocytes.
	317.	The balance of GLI1 and p53 functions, thus, determines cell numbers, and prevalence of p53 restricts GLI1-driven stem cell expansion and tumourigenesis.
	318.	The results of this study demonstrate that gankyrin overexpression downregulates p53 expression and promotes cell proliferation in a zebrafish model. Mdm2 expression was not affected by gankyrin.
	319.	The authors conclude that the E1B 55-kDa protein is not necessary to block activation of p53 in Ad5-infected cells.
	320.	Localization of N-myc downstream-regulated gene 1 and its significant correlation with p53 expression may play an important role in gastric cancer progression.
	321.	Increased PDF mRNA stability in response to hypoxia and cobalt chloride, but not doxorubicin, indicates that p53-dependent induction of PDF expression occurs via diverse mechanisms.
	322.	Results describe thet role of P53/P21 and RUNX 3 in the effects of 5-Aza-2'-deoxycytidine on human cancer cells.
	323.	For urine cytology, immunostaining method with epidermal growth factor receptor and p53 was useful for the differential diagnosis.
	324.	All cases expressed p53 proteins in basal and suprabasal layers. In the basal layer, the nuclei testing positive for p53 were stained intensely, while in the suprabasal layer, cells with slightly stained nuclei were predominant.
	325.	Chk1 affects Cdc25A via rapid phosphorylation and protein turnover, inhibition of Cdc25A transcription by p53-ATF3 is required for the maintenance of cell cycle arrest.
	326.	These results indicate a ROS-independent but p53/retinoblastoma protein-dependent senescence mechanism during hyperoxia.
	327.	miR-145 provides a direct link between p53 and c-Myc in this gene regulatory network
	328.	ATM is a key regulatory protein to promote activation of p53 and Sp1 leading to PrP(C) elevation, which is required to reduce Cu(II) toxic effects and may play an important role in modulation of intracellular copper concentration.
	329.	the essential role of p53 in hyperpigmentation of the skin via the regulation of paracrine-cytokine signaling, both in keratinocytes and in melanocytes.
	330.	The switch from Mnt-Max to Myc-Max during bile duct ligation (cholestasis) and in hepatocytes treated with lithocholic acid is responsible for the induction in p53 and cyclin D1 expression and contributes to apoptosis.
	331.	the Sirt1-dependent proapoptotic effect of Salermide is p53-independent
	332.	epithelial tumor cells can suppress p53 induction in neighboring fibroblasts
	333.	Participation of p53 in the formation of breast fibroadenomas.
	334.	p53 immunocytochemistry detected 87% of the malignancies in specimens from biliary and pancreatic tree brushing in 24 patients with biliary strictures suspected for malignancy.
	335.	neither the TP53 Arg72Pro polymorphism nor the MDM2 SNP309 contributes significantly to either susceptibility or disease severity in systemic lupus erythematosus
	336.	p53 intron 7 ApaI polymorphism may be associated with human NSCLC.
	337.	study showed that p53 expression is directly correlated with undifferentiated endometrial carcinoma, lymph-node involvement and risk of death
	338.	The authors found that liberation of p53 through chemical antagonism of one of its major ubiquitin ligases, MDM2, using the small-molecule Nutlin-3 led to apoptosis of established LCLs and suppressed EBV-mediated transformation of primary B cells.
	339.	Genetic and pharmacologic perturbation of p53 directly influences SULF2 expression in tumor cell lines.
	340.	Transcriptome analyses revealed a consistent up-regulation of polo-like kinase 1 (PLK1) as well as other genes controlling the G(2)/M transition in the cells whose TP53 genes were inactivated compared with those with WT TP53 genes.
	341.	SOX4, a new DNA damage sensor, is required for the activation of p53 tumor suppressor in response to DNA damage.
	342.	Data are the first demonstration that wild-type p53 protein binds to a response element within the EpCAM gene and negatively regulates EpCAM expression, and transcriptional repression of EpCAM contributes to p53 control of breast cancer invasion.
	343.	observations provide support for the idea that up-regulation of IFI16 expression by p53 and functional interactions between IFI16 protein and p53 contribute to cellular senescence.
	344.	The p53 codon 72 polymorphisms are associated with a higher risk of CRC and are associated with more advanced and undifferentiated tumours.
	345.	induction of p53 and apoptosis are reduced by green tea extract in UVB-irradiated human skin independent of transcriptional controls
	346.	MDM2 released from p53 by RITA promotes degradation of p21 and the p53 cofactor hnRNP K, required for p21 transcription
	347.	This study demonstrated that baicalin-induced apoptotic cell death in the breast cancer cells involves the up-regulation of proapoptotic p53 and bax, implying potential crucial roles of bax and p53 in the baicalin-induced apoptosis.
	348.	The combination of the MDM2 SNP309 and the three TP53 polymorphisms appear to be related to a higher grade of endometrial cancer.
	349.	The p53 codon 72 exon 4 BstUI polymorphism is only weakly associated with the risk of endometrial cancer and prognostic factors in Caucasian women.
	350.	Clinical trial of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)
	351.	Observational study of gene-disease association and genetic testing. (HuGE Navigator)
	352.	The experimental data suggest that the ANNEXIN A2 gene may relate to cellular apoptosis induced by p53 gene.
	353.	The P allele of the p53 R72P polymorphism has an increased risk for hepatocellular carcinoma in HbsAg-negative subjects, and exerts a synergistic influence on the risk for HCC when combined with HCC family history and the male gender.
	354.	Tp53 mutant human glioma cells are sensitive to UV-C-induced apoptosis due to impaired cyclobutane pyrimidine dimer removal.
	355.	RYBP decreases MDM2-mediated p53 ubiquitination by interacting with MDM2. RYBP induces cell-cycle arrest and is involved in the p53 response to DNA damage.
	356.	The R allele of the TP53 R72P polymorphism may contribute to the etiology of liver metastases, particularly among those with positive P53 expression tumors. Both TP53 C-8343G and C-1863T may be not associated with colorectal liver metastases risk.
	357.	Effect of ROS on angiogenesis in tumors expressing hot-spot p53 mutants was correlated with their ability to increase a content of HIF1 transcriptional factor responsible for up-regulation of VEGF-A mRNAs.
	358.	CARF plays a dual role in regulating p53-mediated senescence and apoptosis, the two major tumor suppressor mechanisms.
	359.	Data show that hTERT activity or inactivation of p53 can suppress the cell proliferation defects associated with lamin A mutants that are incorrectly processed.
	360.	Ins-72Pro haplotype in p53 with an increased cancer risk in BRCA2 mutation carriers has not been validated
	361.	p53 nucleolar association occurs in lung and bladder carcinomas.
	362.	nucleoplasmic relocation of nucleostemin during nucleolar disassembly safeguards the G2-M transit and survival of continuously dividing cells by MDM2 stabilization and p53 inhibition.
	363.	This selectivity of flavokawain A for inducing a G(2)-M arrest in p53-defective cells deserves further investigation as a new mechanism for the prevention and treatment of bladder cancer.
	364.	ING1 variants may modulate p53 activity and subsequently inhibit hepatoma cell growth by at least two possible mechanisms.
	365.	data suggest that the Mya arenaria p53 shares some functional similarity with human p53 as well as with other invertebrates, positioning the mollusk at a critical juncture in evolution of this gene family
	366.	These findings suggest that the histone methyltransferase SETD2 could selectively regulate the transcription of subset genes via cooperation with the transcription factor p53.
	367.	Results demonstrate for the first time that the 72R allele of the p53 polymorphism has an increased risk for liver metastases in colorectal cancers positive for p53 overexpression.
	368.	p53 is as a cytotoxic bomb that can be triggered by granzyme K, leading to potentiating killing efficacy.
	369.	Up-regulation of p53 gene expression is associated with virus-mediated induction of type-I interferons.
	370.	Low rates of somatic p53 mutations in keratoacanthomas imply a minor role of p53 in the pathogenesis of keratoacanthoma.
	371.	p53 mutation is an initiating mutation in the majority of colitis-associated neoplasia, and K-RAS activation is an alternative gatekeeping mutation.
	372.	Overexpression of p53 oncoprotein is associated with gastric carcinoma.
	373.	the presence of the p53 codon 249 mutation from plasma DNA is significantly associated with hepatocellular carcinoma
	374.	P53 had neither diagnostic nor prognostic relevancein patients with bladder urothelial tumours
	375.	might be markers of depth of invasion or lymph node involvement in patients with gastric cancers
	376.	KLF6 and TP53 mutations are not frequent events in prostate cancer
	377.	Although p53 is mutated in trophoblast, it is functionally incompetent towards matrix metalloproteinases in these cells.
	378.	Study identifies PHLDA3 as a p53 target gene that encodes a PH domain-only protein and finds that PHLDA3 competes with the PH domain of Akt for binding of membrane lipids, inhibiting Akt translocation to the cellular membrane and activation.
	379.	findings of higher DNA concentrations with some p53 mutations in CFDNA from patients with NHL that match the previous reported p53 mutations from tumour DNA may hold promises that CFDNA may serve as a convenient source of tumour-derived DNA
	380.	p53-deficient neuroblastoma cells are largely resistant to nitric oxid (NO) killing and show much reduced maspin and PAI-1 mRNA and protein levels after NO treatment
	381.	A role for p53 in mediating altered trophoblast cell turnover in response to oxidative stress.
	382.	Monocytic leukemia zinc finger (MOZ) interacts with p53 to induce p21 expression and cell-cycle arrest.
	383.	The Snail-p53 binding as the new therapeutic target for K-Ras-mutated cancers including pancreatic, lung, and colon cancers.
	384.	p53-Mdm2 protein-protein and p53 mRNA-Mdm2 interactions affect Mdm2-mediated control of p53 expression using the Phe19Ala p53 mutant.
	385.	Spy1 fulfills a novel regulatory role in the intrinsic DNA damage response and maintains the balance between checkpoint activation, apoptosis, repair and cell cycle progression in response to exogenous or intrinsic damage.
	386.	p53 Mutations is associated with carcinoma of the esophagus and gastroesophageal junction
	387.	The p53-dependent transcriptional regulation of p21 in response to DNA damage by ultraviolet radiation and ionizing radiation compared.
	388.	The export of p53 from the nucleus is not sufficient to activate its cytoplasmic apoptotic function which may depend on the ability to deubiquitinate cytoplasmic p53.
	389.	Non-smoking and non-drinking patients with squamous cell carcinoma have the same risk for developing multiple tumors as their smoking and drinking counterparts without an increased expression of p53.
	390.	results support the hypothesis that p53 function is suppressed by aberrant HDM2 activity and suggest the possibility of targeting the p53-HDM2 regulatory axis as a therapeutic strategy in synovial sarcoma
	391.	53BP1 Tudor domain recognition of p53 dimethylated at lysine 382 in DNA damage signaling
	392.	TP53 mutation is highly recurrent in basal-like carcinoma independently of BRCA1 status, but not a common feature of BRCA1 luminal tumors.
	393.	combined alpha-methylacyl coenzyme A racemase/p53 analysis may represent a helpful tool to confirm dysplasia in inflammatory bowel disease.
	394.	the new oncogenic p53 target, PRL-1, may contribute to tumor development by the downregulation of p53 by a negative feedback mechanism.
	395.	Hdm2 is expressed in pancreatic cancer cells as a result of activated Ras signaling, and regulates cellular proliferation and the expression of target genes by p53-independent mechanisms.
	396.	E6 F47R-induced cellular senescence is strongly dependent on p53 signaling pathway.
	397.	JS-K inhibits E1 activity and kills transformed cells harboring wild-type p53.
	398.	A TP53 single nucleotide polymorphism is critical for oncogenesis of glioblastoma in young patients.
	399.	Patients from Kashmir Valley, INdia with TP53 mutant esophageal squamous cell tumor had lower zinc levels than those with no mutation.
	400.	The aim of the study was to evaluate the correlation between clinical characteristics, histopatologic features and c-erbB-2 as well as p53 expression in cancer tissues.
	401.	The results show that p53 mutations characterize a small biologically aggressive subgroup of prostate cancers with a high risk of progression after prostatectomy.
	402.	analysis of p53 gene in prostate adenocarcinoma showed several mutations in high Gleason patients, according to tumor advanced stage; results showed localization of p53 & T antigen (TAg) into cytoplasm, but in TAg-negative tumors, p53 was nuclear
	403.	A homozygous p53 R248W gain-of-function mutation as the result of a CGG to TGG transition was identified in one of seven sebaceous gland carcinomas. It has been demonstrated previously that p53 R248W mutants inactivate ATM-directed HRR.
	404.	demonstrated no evidence for association of MDM2 SNP 309 or TP53 Arg72Pro allelic variants alone, or in combination, with overall survival (Figure 1A), progression free survival, relapse free survival or time to transformation
	405.	CPEB controls senescence and bioenergetics in human cells at least in part by modulating p53 mRNA polyadenylation-induced translation
	406.	p53 codon 72 polymorphism (Arg72Pro) frequencies with respect to the susceptibility and the clinical outcome of patients with Soft tissue sarcomas.
	407.	relation with p53 protein expression, p53 gene codon 72 polymorphism and infection with HPV DNA with pterygium
	408.	Results suggest that apoptosis inhibitory proteins are highly induced in squamous cell carcinoma/mutated p53 cells after heat treatment when compared to control cells.
	409.	These results provide a structural explanation for the dominant-negative effect of p53 and its lack of transcriptional activity.
	410.	Polygonatum cyrtonema lectin induces apoptosis and autophagy via a mitochondrial-mediated ROS-p38-p53 pathway
	411.	p53-dependent downregulation is consistent with an oncogenic function of RHAMM and the recently reported tumor-suppressive function of CD44 transcriptional repression by p53.
	412.	there was no association between the p53 antigen G72C polymorhphism and susceptibility or course of disease in patients with Wegeners granulomatosis
	413.	Only a small fraction of naturally occurring sequence variations of TP53 cause measurable perturbation of p53 function.
	414.	p53 may induce cell cycle arrest not only by well described mechanisms involving the induction of cyclin-dependent kinase inhibitors but also by the recruitment of pathways that reduce the availability of intracellular iron
	415.	Mdm2-mediated control of p53 synthesis and degradation has evolved in the p53 mRNA sequence and its encoded amino acids.
	416.	incidence and prognostic impact of TP53 mutations in a cohort of patients with adverse cytogenetics and those with losses on chromosome 17p
	417.	Id-1 regulates Bcl-2 and Bax expression through p53 and NF-kappaB in MCF-7 breast cancer cells
	418.	the identification and functional characterization of a novel TP53 germinal mutant allele (Cys275Phe c.824G > T p.C275F) in a large Italian Li-Fraumeni syndrome family
	419.	TP53 mutations in chronic lymphocytic leukemia were significantly associated with del (17p) and complex cytogenetic abnormalities
	420.	ANKRD11 has a role as a p53 coactivator and may be involved in a regulatory feedback loop with p53
	421.	additional inactivation of p53 in malignant primaries and benign recurrences contributes to myoepithelial neoplastic transformation and aggressive tumour growth.
	422.	the detection of a TP53 abnormality in early stage CLL is often associated with progressive disease,however, a subset of these cases with mutated IGHV genes may have stable disease for many years, never requiring therapy
	423.	Alterations in both the p53 and p16-Rb pathways are associated with squamous cell carcinoma arising in mature cystic teratoma.
	424.	Pleurotus ostreatus inhibits proliferation of human breast and colon cancer cells through p53-dependent as well as p53-independent pathway.
	425.	Report differential role of diphenyleneiodonium, a flavoenzyme inhibitor, on p53-dependent and -independent cell cycle progression.
	426.	Proton beam induces apoptosis of hypoxic tumor cells by the p53-dependent and p38/JNK MAPK signaling pathways.
	427.	wild type p53 suppressed the S100A6 promoter up to 12-fold in a dose-dependent manner
	428.	p38 kinase which was activated during p53-induced senescence was not observed in vitamin C-treated EJ cells
	429.	TsA markedly down-regulated the expression of cyclin D1 and CDK4, up-regulated the expression of p21WAF1 and p53 and induced cell cycle arrest at the G1 phase in MCF10A-ras cells
	430.	Meta-analysis of gene-disease association and gene-environment interaction. (HuGE Navigator)
	431.	REVIEW. p53 represses RHAMM and CD44 expression
	432.	These results highlight the prognostic value of CDK4 amplification and of simultaneous EGFR-p53 alterations in the clinical outcome of patients with primary GBM.
	433.	The inactivation of TP53 is similar in familial pancreatic adenocarcinomas as in sporadic pancreatic adenocarcinomas.
	434.	p53 in mitochondria may be a component of an error-repair pathway and serve as guardian of the mitochondrial genome.
	435.	c-Abl and p53 are important for execution of the cell death program initiated in A2E-laden RPE cells exposed to blue light, while JNK might play an anti-apoptotic role
	436.	direct interaction between NM23-H1 and macrophage migration inhibitory factor (MIF) is critical for alleviation of MIF-mediated suppression of p53 activity
	437.	Alterations in the p53 gene may be indicative of poorer prognosis and greater recurrence in patients with urothelial bladder tumor.
	438.	Strap regulation reflects the coordinated interplay between different DNA damage-activated protein kinases, ATM and Chk2 (Checkpoint kinase 2), where phosphorylation by each kinase provides a distinct functional consequence on the activity of Strap.
	439.	p53 expression seems to negatively influence survival in non-smoking non-alcoholic patients with squamous cell laryngeal carcinoma.
	440.	expression of miRNAs is downregulated in senescent cells and in breast cancers harboring wild-type p53. These miRNAs are repressed by p53 in an E2F1-mediated manner
	441.	The crystal structures of the p53 core domain incorporating the hot spot mutation R249S, the core domain incorporating R249S and a second-site suppressor mutation H168R and its sequence-specific complex with DNA and of the triple mutant, were determined.
	442.	Genotoxic stress promotes the p53-dependent up-regulation of the homologous miRNAs miR-192 and miR-215.
	443.	Results suggest that nonactivated p53 has limited binding activity, whereas upon activation it binds to essentially all its targets. Additional triggers are most likely required to activate the transcriptional program of p53.
	444.	TP53 methylation was probably not implicated in gastric carcinogenesis
	445.	p53 siRNA enhanced reprogramming efficiency of pluripotent stem cells generation induced from human adult fibroblasts
	446.	Doublets in the EGFR and TP53 genes in human lung cancer are elevated about eight- and three-fold, respectively, relative to spontaneous doublets in mouse
	447.	In this immunohistochemical study, 80% of all vulvar intra-epithelial neoplasia were negative for p53 tumor suppressor protein.
	448.	TP53 mutation but no CHEK2*1100DelC variant in familial gliomas.
	449.	GBP-2 is regulated by p53 and may have a role in esophageal squamous cell carcinomas
	450.	Completely inhibits Saccharomyces cerevisiae growth under minimal media conditions and down regulates thioredoxin expression.
	451.	epirubicin-cyclophosphamide treatment induces senescence-like features in TP53 wild-type tumor, while in TP53 mutated tumors, chemotherapy induces mitotic catastrophe and tumor death
	452.	Skin cells grown in culture showed a notable decrease in the UVB fingerprint mutation on the p53 tumor suppressor gene in fibroblasts during proliferation.
	453.	HER-2/neu, AR, and p53 are expressed in a subset of histologically and clinically benign pleomorphic adenomas. These markers cannot be used to reliably predict early carcinomatous transformation in pleomorphic adenoma.
	454.	Protein expression neither of p16(INK4a) nor of p53 correlated with high-risk human papillomavirus status
	455.	TP53 levels were not helpful in identifying patients who would benefit from neoadjuvant treatment of rectal cancer.
	456.	Polymorphism Arg72Pro in tumor suppressor gene TP53 increases the risk of lung cancer, especially for small cell lung cancer and heavy smokers.
	457.	analysis of the coordinated immediate responses by p16INK4A and p53 pathways in UVB-irradiated human skin cells
	458.	analysis of the expression of fatty acid synthase, Ki-67 and p53 in squamous cell carcinomas of the larynx
	459.	TP53 mutations may have a role in progression of breast cancer
	460.	p53 and GLI1 may have a role in tumor cell survival
	461.	Report genetic alterations of TP53 in Korean colorectal cancer patients.
	462.	A novel p53-dependent transcriptional mechanism regulates adaptor protein p66shc expression operative in the vascular endothelium and may be important in impairing endothelium-dependent vascular relaxation.
	463.	data suggests that TP53 mutations are associated with poor outcome in diffuse large B-cell lymphoma of germinal center subtype patients
	464.	PPARgamma and TP53 genes may be candidates for molecular markers in pediatric MDS, and that these potentially recurrent deletions could contribute to the identification of therapeutic approaches in primary pediatric MDS
	465.	p53 directly affects hPar1 expression and function, thus providing evidence for direct binding between p53 and hPar1 chromatin.
	466.	S100A6 is induced by tumor necrosis factor-alpha via an NF-kappaB-dependent mechanism, serving a role in homeostasis to limit tumor necrosis factor-alpha-induced apoptosis by regulating p53 phosphorylation
	467.	This review concludes that a selective gain of pro-survival functions of wild-type p53 in cancer cells will confer a survival advantage that counteracts tumor therapy.
	468.	Inhibition of MT2A expression by siRNA in the HIPK2 knockdown cells restored p53 transcription activity.
	469.	Ets-1 binds cooperatively to the EBS palindrome of the hp53 promoter.
	470.	with aging there is an increase of mutant like conformation state of p53 in peripheral blood cells, which is more pronounced in Alzheimer Disease patients
	471.	incidence of additional cytogenetic abnormalities, reflecting an increased chromosomal instability, was higher in >or=5%TP53-deleted cases
	472.	The authors show that Pirh2-p53 interaction is dependent on the C-terminal zinc binding module of Pirh2, which binds to the tetramerization domain of p53.
	473.	Different from ERbeta, p53 interacts with HDAC1 and CtBP1 and forms an inhibiting transcriptional complex that could compete for binding to Sp1 sites with ERalpha transcriptional complex and inhibit BRCA2 transcription more significantly
	474.	15d-PGJ(2) induces vascular endothelial cell apoptosis through the signaling of JNK and p38 MAPK-mediated p53 activation both in vitro and in vivo
	475.	Resveratrol displays converse dose-related effects on fluorouracil-evoked colon cancer cell apoptosis: the role of p53 is reported.
	476.	The role of p53 in the sustained phosphorylation of c-Jun-N-terminal kinase mediating melanoma apoptosis induced by 2-acetyl furanonaphthaquinone is reported.
	477.	4-HNE is involved in p53-mediated signaling in in vitro cell cultures as well as in vivo that can be regulated by glutathione transferase
	478.	STX6 can be induced by DNA damage and Mdm2 inhibitor Nutlin-3 in a p53-dependent manner.
	479.	Epistatic analysis that p53 inhibition results in a maximum level of autophagy.
	480.	the kinetic stabilization of microtubules enhances the microtubule-mediated transport of p53 into the nucleus
	481.	Methylation on arginine residues is an underlying mechanism of control during the p53 response.
	482.	These data indicate that elevated Skp2 expression may overcome p53-dependent cell cycle checkpoints in melanoma cells and highlight Skp2 actions that are independent of p27(Kip1) degradation.
	483.	Results describe the possible involvement of p53 in the osteocyte apoptosis observed in Idiopathic osteonecrosis of the femoral head.
	484.	Principal component analysis was performed on the atomic contact maps of an experimentally restrained ensemble of the human p53 transcriptional activator domain.
	485.	p53 codon 72 polymorphism appears to be an independent prognostic factor in gastric cancer patients treated with 5-FU-based adjuvant chemotherapy.
	486.	maximum expression of p53-Ser15(P) coincided in time with the peak of Chk2 activation
	487.	PML disruption by EBNA1 requires binding to the cellular ubiquitin specific protease, USP7 or HAUSP, but is independent of p53.
	488.	the cytoplasmic localization of p53 as the most important feature for p53-mediated autophagy inhibition.
	489.	p53 phosphorylation and localization status is associated with expression of ADP ribosylation factor like 2.
	490.	oxidative modification of p53 could be involved in the neuronal loss observed in neurodegenerative conditions
	491.	TP53 mutations are associated with chemoresistance in breast cancer, defined as progressive disease on therapy for mutations affecting p53 loop domains L2/L3).
	492.	Aberrant DNA methylation was not associated with p53 mutations in ovarian carcinoma.
	493.	knockdown of endogenous MBP-1 is involved in cellular senescence of HFF through p53-p21 pathway.
	494.	Ubiquitin over-expression promotes the destabilization of the ubiquitin protein ligase E6AP, by a mechanism involving self-ubiquitination, and the stabilization of p53.
	495.	Two conserved CPEs in the p53 3'UTR regulate stability and translation of a reporter mRNA in non-irradiated as well as irradiated cells.
	496.	G > A polymorphism at intron 6 of p53 may contribute to the level of DNA damage in occupational exposure to vinyl chloride.
	497.	Data show that nitric oxide derived from S-nitrosoglutathione activates ASK1 in THP-1 human myeloid macrophages, induces accumulation of HIF-1alpha protein, and induces accumulation of p53 in normal but not HIF-1alpha knockdown THP-1 cells.
	498.	TP53 gene expression was significantly higher in colorectal cancer patients than in healthy volunteers.
	499.	three different COX-2 mutations and five different P53 mutations are associated with non-small-cell lung carcinoma
	500.	Strong p53 nuclear staining was detected in smokeless tobacco keratosis, squamous cell carcinoma and alveolar ridge keratoses.
	501.	Influence of tetramerization on site-specific post-translational modifications of p53 are reported.
	502.	Results suggest that the Arg/Arg genotype polymorphism of p53 may represent a potential risk factor for the development of lung cancer independent of the human papillomavirus infection.
	503.	Tat contributes to neuronal degeneration through activation of a pathway involving p53 and p73.
	504.	the TP53 polymorphism, at the 347 residue, is not associated with any clinicopathological findings of patients with breast cancer.
	505.	Ethnicity determines association of p53Arg72Pro alleles with cervical cancer in China.
	506.	The data showed that hepatocellular carcinoma patients had a significantly higher mean anti-p53 antibody values (p=0.0001), than both liver cirrhosis patients and healthy control groups.
	507.	These observations suggest that most endopolyploid tumour cells are not reproductively inert and that Aurora-B may contribute to the establishment of resistant tumours post-irradiation.
	508.	functional inactivity and mutations of p53 differentially affect TS, potentially influencing response to TS inhibitor-based treatment
	509.	Expressed in most dysmorphic neurons in focal cortical dysplasia type II.
	510.	crystal structure of N-terminal domain of Mdmx bound to 15-residue p53 peptide was determined; structure reveals that although principle features of Mdm2-p53 interaction are preserved, the Mdmx hydrophobic cleft on which the p53 peptide binds is altered
	511.	Describe TP53 expression in developing pituitary gland.
	512.	findings suggest that the combined variants of p53 and p73 significantly increase the risk of HPV16-associated oral cancer, especially among never-smokers
	513.	overexpression of p-ATF2, p-STAT3 and possibly p53, but not p63 or p73, may contribute to the tumorigenesis of cutaneous vascular tumors.
	514.	Proteasome inhibition-mediated premature cell senescence can only be initiated and maintained in the presence of functional p53.
	515.	direct interaction of p53 with mitochondrial antiapoptotic proteins including Bcl-2 is the major route for apoptosis induction in CLL cells
	516.	Report relationship of Ki67, TP53, MDM-2 and BCL-2 expressions with WHO 1973 and WHO/ISUP grades, tumor category and overall patient survival in urothelial tumors of the bladder.
	517.	The presence and absence of a dominant negative p53 mutation may thus provide a predictor of early recurrence in oral SCC patients.
	518.	interaction of PI3K/Akt/mTOR and p53 pathways after their simultaneous blockade using the dual PI3K/mTOR inhibitor PI-103 and the Mdm2 inhibitor Nutlin-3.
	519.	p53 mutations are not always associated with malignant transformation in epithelioid angiomyolipoma.
	520.	p53 codon 72 SNP ws not associated with susceptibility to or age at onset of OSCC or OSF. p53 codon 72 SNP Arg/Arg polymorphism was associated with progression of OSCC, OS and DSF in irradiated patients.
	521.	An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma.
	522.	polymorphism at codon 72 modulates the risk of lung cancer in Brazilian patients with African ethnical background
	523.	The p53 codon 72 and 16-bp duplication polymorphisms were not associated with the increased risk of gastric cancer and did not seem to contribute to gastric cancer susceptibility among Koreans.
	524.	expression of p53 and Ki-67 antigen is helpful to predict tumor recurrence and prognosis in skull base chordomas.
	525.	TP53 inactivation may have a role in progression of chronic lymphocytic leukemia
	526.	Germline p53 mutation is associated with adrenocortical carcinoma and subsequent osteosarcoma
	527.	integrin beta4 is implicated in and associated with p53 in autophagy of lung cancer cells
	528.	Results investigate eight polymorphisms in the region encompassing exon 2 to 4 of TP53 and examine their association with cervical cancer risk.
	529.	Mdm2 regulates p53 levels also by targeting ribosomal protein L26 for polyubiquitylation and proteasomal degradation.
	530.	Myc as an important target for cooperative actions of p53 and Pten in the regulation of normal and malignant stem/progenitor cell differentiation, self-renewal and tumorigenic potential
	531.	Influence of prothymosin alpha and its mutants on activity of the p53 tumor suppressor
	532.	Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain.
	533.	p53-independent events regulating expression of protein-coding genes and microRNAs within the network can define the cellular outcome of p53 activation.
	534.	TP53 mutation is associated with metastatic pulmonary adenocarcinomas.
	535.	CK1 has a role as the Ser20 site kinase for p53 in DNA virus-infected cells
	536.	Its loss of function is critical for the molecular pathogenesis of uterine papillary serous carcinoma.
	537.	senescence of primary NHP cells expressing progenitor cell markers CD44, alpha2beta1, p63, hTERT, and CK5/CK18, involves loss of telomerase expression, up-regulation of p16, and activation of p53.
	538.	A375 cells exposed to selenocystine showed an increase in levels of total p53 and phosphorylated p53
	539.	MAP1B light chain can interact with the tumor suppressor p53.
	540.	P53 has a role in malignancy and epithelioid differentiation in GISTs
	541.	these results imply a regulatory connection between the FA pathway and activation of TP53 for responding to DNA damage
	542.	This study provides evidence of a positive association between parameters reflective of angiogenesis, and p53 expression in HCCs
	543.	vascular endothelial growth factor, receptor KDR and p53 protein are expressed in transitional cell carcinoma of the bladder
	544.	IL-8 and p53 protein expression is regulated through inverse activation of the p38 MAPK and the JNK pathways and the NF-kappaB p65 expression
	545.	p53 over-expression predicted both transformation to diffuse large B-cell lymphoma and poorer overall and cause-specific survival of patients with follicular lymphoma.
	546.	Results describe the location and expression of human papillomavirus 18 E6 and p53 proteins.
	547.	sarcomatous transformation of diffuse-type tenosynovial giant cell tumors involves aberrations of cyclin A, P53, and chromosome arm 15q
	548.	analysis of the intramolecular interaction in FOXO3a and its binding with p53
	549.	Immunohistochemistry using antibodies to determine the protein expression of Fas, Fas-L, Bax, Bcl-2, p53 and c-Myc in skin of venous ulcer patients.
	550.	An unusual p53 mutation detected in Burkitt's lymphoma: 30 bp duplication.
	551.	Hsf1 is required for p53 nuclear importation and activation, which implies that heat shock factors play a role in the regulation of p53.
	552.	results demonstrate that in p53-deficient human gastric cancer cells, restoration of functional miR-34 inhibits cell growth and induces chemosensitization and apoptosis, indicating that miR-34 may restore p53 function
	553.	Alleles of three noncoding TP53 markers were associated with NTD risk.
	554.	Proline oxidase, a p53-induced gene, targets COX-2/PGE2 signaling to induce apoptosis and inhibit tumor growth in colorectal cancers
	555.	Together these results identify ASPP2 as a bona fide DDA3 interacting protein, and suggest that the ASPP2/DDA3 interaction may inhibit ASPP2 in stimulating the apoptotic signaling of p53.
	556.	concomitant presence of somatic alteration in mtDNA and the DNA binding domain of the p53 gene facilitates cell survival and tumorigenesis
	557.	The protein structure prediction of CP2 family in order to elucidate the molecular mechanism of the CP2-directed regulation of gene expression.
	558.	Transcription from P2 is believed to be controlled by p53 and a single-nucleotide polymorphism (SNP309, T>G) in P2 is reported to be associated with increased risk for, and early development of, malignancies
	559.	These results suggest that p53 influences TLR3 expression and function and highlight a role of p53 in innate immune response in epithelial cells.
	560.	Data suggest that the R3IM motif of DSS1, in conjunction with the complexes of 19S RP and 20S core particle, regulates proteasome interaction through RPN3/S3 molecule, and utilizes a specific subset of poly-ubiquitinated p53 as a substrate.
	561.	sPDZD2 sensitized mutant p53-positive DU145 cells and wild-type p53-positive MCF-7 cells to apoptosis induction through genotoxic stress imposed by sub-lethal concentration of hydrogen peroxide
	562.	a TP53 mutation in follicular lymphoma may have a role in disease progression
	563.	Phosphorylation of MUC1 by Met modulates interaction with p53 and MMP1 expression.(
	564.	Damage of exon 5 of p53 gene by arsenic is associated with precarcinomas and carcinomas.
	565.	homozygous TP53 arginine genotype is not a potential risk factor for development of penile squamous cell carcinoma in subjects of African ethnicity.
	566.	Results suggest the involvement of the p53 codon 72 polymorphism in the skin tanning response and potential interaction with skin pigmentation on melanoma risk.
	567.	the deregulation of both the p53 and the p73 pathways plays an important role in inducing head and neck cancers
	568.	Elevated p53 expression is associated with dysregulation of the ubiquitin-proteasome system in dilated cardiomyopathy.
	569.	Body mass index is not associated with a higher TP53 mutation frequency in bladder tumors
	570.	IGF-1R-dependent UVB-induced premature senescence required the phosphorylation of p53 serine 46.
	571.	Observational study and genome-wide association study of gene-disease association. (HuGE Navigator)
	572.	Noncanonical DNA motifs as transactivation targets by wild type and mutant p53 are reported.
	573.	Patients with head and neck squamous cell carcinoma having a high portion of tumour cells expressing p53 had a shorter survival than the other groups
	574.	Monitoring for sequential change of serum p53-Abs before and after radiotherapy in patients with esophageal carcinoma is uuseful to evaluate the response to the treatment and prognosis of the patients.
	575.	ReportGene expression profiles modulated by the carcinogen aristolochic acid I in human cancer cells and their dependence on TP53.
	576.	L11 cooperates with L5, resulting in a robust inhibition of the E3 activity of MDM2, and a stabilization and activation of p53 approaching that achieved by p14(ARF).
	577.	PCAF regulates the balance between cell-cycle arrest and apoptosis in hypoxia by modulating the activity and protein stability of both p53 and HIF-1alpha.
	578.	the germinal center phenotype, P53 accumulation, and t(14;18) were independent factors for simian virus 40 association (P=0.029, 0.006, and 0.014, respectively) in diffuse large B-cell lymphomas
	579.	MGMT promoter methylation modulated by p53 status could partially promote p53 mutation occurrence in advanced lung tumors
	580.	TP53 Pro47Ser and Arg72Pro SNPs are not associated with risk and prognosis of human gliomas
	581.	Suppression of inhibitor of differentiation 2, a target of mutant p53, is required for gain-of-function mutations in colonic and pancreatic neoplasms
	582.	Ki-67- and p53-immunostained cells were mainly located in the suprabasal layers. p63-positive cells were found throughout the lining cystic epithelium.
	583.	p53 overexpression strongly downregulates the transcriptional efficiency driven by an H ferritin promoter construct containing only the NF-Y recognition sequence.
	584.	The role of p53, followed by Ki-67, as predictive factors
	585.	findings provide a molecular rationale for the role of human Spot 14 protein in the p53-dependent transcriptional activation of specific genes via diverse pathways in cells
	586.	There is a molecular association of the p53 codon 72 arginine allele with tumor aggressiveness and treatment resistance in advanced breast cancer.
	587.	These results indicate that the E1B protein fulfills an early function that correlates efficient entry into the late phase with the localization of E1B and p53 in the nucleus of Ad5-infected normal human cells.
	588.	p53 expression in liver tissue was higher in the hepatitis C virus-associated hepatocellular carcinoma (HCC) patients compared to normal controls & correlated well with the HCC grade; p53 is implicated in the poor prognosis of HCV-HCC
	589.	p53 mutations are present in a subset of pituitary carcinomas and are usually associated with a high percentage of tumor cells overexpressing the p53 protein.
	590.	MMR-dependent intrinsic apoptosis is p53-independent, but stimulated by hMLH1/c-Abl/p73alpha/GADD45alpha retrograde signaling
	591.	Several members of a Malaysian family had a duplication of a GGCGTG motif starting at nucleotide 17579 in exon 10, resulting in an in-frame insertion of two amino acids between residues 334 & 336 in the tetramerization domain of the p53 protein.
	592.	Results further strengthen the association between germline TP53 mutations and childhood choroid plexus carcinomas, even when occurring in the absence of familial tumour susceptibility.
	593.	p53 mutation was observed in 87% of esophageal squamous cell carcinoma, in 80% of esophageal dysplasia, in 0% of normal mucosa.
	594.	Transcription regulation assays with MCL-1 promoter deletion mutants showed that most of the p53 inhibitory effect was mediated by the -41 to +16 bp promoter binding sites only for TATA-binding protein and other basal transcription factors.
	595.	Andrographolide inhibits human colorectal cancer Lovo cell growth by G1-S phase arrest and inducing the expression of p53, p21 and p16.
	596.	TAF6delta has a pivotal node in a signaling pathway that controls gene expression programs and apoptosis in the absence of p53
	597.	data link EWS-FLI1 to the NOTCH and p53 pathways and provide a plausible basis both for NOTCH tumor suppressor effects and oncogenesis of cancers that retain wild-type p53
	598.	wild-type TP53 in CRC cells favours the progression of tumours expressing markers for hypoxia in their stroma, rather than in the epithelial compartment
	599.	p53 represses the PDGFRB promoter, facilitating the p53-induced apoptosis, whereas tumor cells with p53 mutation or a high level of DeltaNp73 or Myc could become refractory to the regulation.
	600.	Zac1 might be involved in regulating the p21(WAF1/Cip1) gene and protein expression through its protein-protein interaction with p53 and HDAC1 in HeLa cells.
	601.	These observations suggest that the relative cytoplasmic abundance of PTB protein, under DNA-damaging conditions, might contribute to regulating the coordinated expression of the p53 isoforms.
	602.	KAI-1 and p53 show inverse expression in uterine and endometrial carcinomas and sarcomas. The reduced KAI-1 expression may be the result of dysregulated p53 function and could be a step in endometrial carcinogenesis.
	603.	differences in cellular responses to stress between the TP53 codon 72 genotypes contribute to the differences in cancer incidence and longevity observed earlier for these genotypes
	604.	Elevated levels of pro-apoptotic p53 and its oxidative modification by the lipid peroxidation product, HNE, in brain from subjects with amnestic mild cognitive impairment and Alzheimer's disease are reported.
	605.	These results represent a definitive argument demonstrating that Li-Fraumeni syndrome results from TP53 haplodeficiency.
	606.	neither the Ins16bp or Arg72Pro polymorphisms of p53 considered separately, nor any related haplotype, were associated with breast cancer risk in BRCA-mutation negative familial cases.
	607.	confirmed a high incidence of TP53 mutations in AML with a complex aberrant karyotype and demonstrated that TP53 mutations are very rare in AML without a complex aberrant karyotype
	608.	BAK oligomerization by p53 utilizes conserved residues of the p53 DNA binding domain
	609.	Trichostatin A causes p53 to switch oxidative-damaged colorectal cancer cells from cell cycle arrest into apoptosis.
	610.	observations confirm a new role for p53 as a uPA mRNA binding protein that down-regulates uPA mRNA stability and decreases cellular uPA expression
	611.	Prognosis of patients with p53-overexpressing ovarian cancer is affected by the MHC class I status of tumour cells and ovarian cancer patients can generate immune responses to the p53 tumour antigen.
	612.	the human glutathione S-transferase P1 gene is a novel transcriptional target of the p53 tumor suppressor gene
	613.	p53 status and efficacy of primary anthracycines/alkylating agent-based regimen according to breast cancer molecular classes are reported.
	614.	tumor cell incubation with pioglitazone results in increased levels of p53 and p27 and decreased levels of cyclin D1
	615.	structural analysis of the tumor suppressor p53 [review]
	616.	Data show that germ cell single base substitution mutation frequencies are very similar to somatic tissue TP53 mutation frequencies.
	617.	an interactive effect was detected such that MDM2 TT TP53 Arg/Arg double homozygotes, and individuals carrying both a MDM2 G allele and a TP53 Pro allele, were at increased risk of t-AML
	618.	These results indicate that acidic domain of MDM2 provides essential information for acetyltransferase p300 and deacetylase HDAC1 and is indispensable for MDM2 to negatively regulate the acetylation of p53.
	619.	results suggested that beta1,4GalT II might serve as a target gene of p53 transcription factor during adriamycin-induced HeLa cell apoptosis, which elucidated a new mechanism of p53-mediated cell apoptosis
	620.	MIF physically associates with p53 and negatively regulates p53 function.
	621.	identify OKL38 as a novel p53 target gene that is regulated by Peptidylarginine deiminase 4 and plays a role in apoptosis
	622.	Cyclic pifithrin-alpha sensitizes wild type p53 tumor cells to antimicrotubule agent-induced apoptosis
	623.	mutations in different exons of p53 are related to different phenotypes
	624.	c-Abl and Cdk5 cooperatively regulate maximal activation of p53, resulting in neuronal death in response to oxidative stress by hydrogen peroxide.
	625.	crystallographic anlaysis of molecules that bind to p53 from a drug screening assay
	626.	PEDF induces human umbilical vein endothelial cells apoptosis through the sequential induction of PPARgamma and p53 overexpression.
	627.	Report p53 expression in abberant crypt foci and colorectal neoplasms.
	628.	p53 levels were significantly higher in lung parenchyma in subjects with emphysema
	629.	These results establish a link between the p53 tumor suppressor and RNA processing via hnRNPA2/B1 and RNA Helicase A.
	630.	a novel role for p53 as an mRNA-binding protein that regulates increased PAI-1 expression and stabilization of PAI-1 mRNA in human lung epithelial and carcinoma cells
	631.	investigation of the involvement of the CDKN2A, CDKN2B and p53 genes in actinic keratosis (AK) and in the progression of AK to squamous cell carcinoma
	632.	confirmed 27 TP53 mutations in 68 primary breast cancers analyzed by high-resolution melting curve scanning and direct sequencing. Using scanning and automatic calling, there was high specificity (>95%) across all DNA preparation methods
	633.	Pim-1 induces the p53 pathway in cultured cells and correlate with increased Mdm2 in mantle cell lymphoma
	634.	Chromosome instability in human hepatocellular carcinoma depends on p53 status and aflatoxin exposure.
	635.	ATO-induced activation of Chk2/p53 and p38 MAPK/p53 apoptotic pathways can be enhanced by siRNA-mediated suppression of Wip1 expression, further indicating that ATO inhibits Wip1 phosphatase in vivo
	636.	Point mutation at exon 5 of the p53 gene was present in colonic and stomach neoplasms, they could be considered to be of the same origin originated from a common epithelial stem cells.
	637.	inflammatory levels of NO inhibit epithelial cell migration, because of suppression of ERK1/2 signaling, and activation of HIF-1alpha and p53, with potential consequences for epithelial repair and remodeling during airway inflammation
	638.	Fbw7 regulates the activity of endoreduplication mediators and the p53 pathway to prevent drug-induced polyploidy.
	639.	the functional regulation of p53 by triptolide was mediated by an intranuclear association of p53 with glycogen synthase kinase-3beta (GSK3beta), which was inactivated by protein kinase C (PKC).
	640.	analysis of 31 bilateral breast cancer (biBC) pairs (12 synchronous & 19 metachronous cases); TP53 sequence alterations were detected in 7 patients; 2 had mutations in both neoplasms & in 5 biBC pairs the TP53 gene was affected in only 1 of the tumors
	641.	a high level of p53 downregulates the beta-catenin expression, but this effect is attenuated by non-functional AXIN2 or betaTrCP in lung cancer.
	642.	study examined the presence of mutations in TP53 at codon 249 (Ser-249, considered as a hallmark of mutagenesis by aflatoxin) and in CTNNB1 in circulating free DNA of patients with hepatocellular carcinoma or chronic liver disease from Alexandria, Egypt
	643.	Extra-nuclear p53-dependent apoptosis may constitute a fail-safe mechanism against dominant inhibition.
	644.	The existence of a functional binding site for the tumor suppressor p53 near the proximal CCAAT box and the fact that the basal expression of annexin A1 in human colon adenocarcinoma cells is driven by p53 at the transcriptional level, is shown.
	645.	analysis of solar light-induced p53 mutagenesis in SKH-1 mouse skin
	646.	Hibiscus syriacus extract exhibits a cytotoxic effect on lung cancer cells by activation p53 and AIF.
	647.	No significant difference in the distribution of p53 codon 72 genotypes was observed between endometriosis patients and controls.
	648.	AEN is an important downstream mediator of p53 in apoptosis induction in cancer.
	649.	Results could not indicate significance of P53 mutations for evaluation of residual clone malignancy.
	650.	polymorphisms and haplotypes in the TP53 gene, including Arg72Pro, were not significantly associated with lung cancer in a Korean population
	651.	These results suggest a role of PAD4 in the regulation of p53 target gene expression.
	652.	Study shows that mitochondrial p53 is highly efficient in inducing the release of soluble and insoluble apoptogenic factors by severely disrupting outer and inner mitochondrial membrane integrity.
	653.	stabilization of p53 mRNA in hepatocellular carcinoma cells is involved in TIP30 control of cellular oxidative stress and apoptosis induction
	654.	TP53 gene mutations of lung cancer patients in upper northern Thailand and environmental risk factors are reported.
	655.	5-Aza-2'-deoxycytidine restores proapoptotic function of p53 in cancer cells resistant to p53-induced apoptosis.
	656.	The association oxaliplatin/TRAIL should be restricted to patients harbouring a non-functional p53 protein.
	657.	p53 regulated transcripts including Puma/BBC in tetraploid but not diploid tumor cells is modulated by Chk1 inhibition
	658.	review of kinase-independent interaction of FAK with p53with focus on FAK and p53 signaling, which link signal transduction pathways
	659.	Study of conformational mutant p53 as a new putative marker to discriminate Alzheimer disease(AD) from non-AD patients.
	660.	No association was detected between the TGFB1, IL10, TP53, and HMOX1 genes and DGF. The G allele of the TNF polymorphism rs3093662 was associated with DGF in an adjusted analysis.
	661.	Impaired p53 function in tumour stroma might be related to genomic instability and could enable stromal cell survival in the destabilising tumour microenvironment.
	662.	A feedforward loop involving c-Myc and eIF4F that serves to link transcription and translation and that could contribute to the effects of c-Myc on cell proliferation and neoplastic growth.
	663.	ATM is a key mediator of the MT-hTer-47A dysfunctional telomere response, even in cells lacking wild-type p53.
	664.	Nuclear TP53 accumulation may be relevant in patient's prognosis in neuroblastic tumors.
	665.	Expression of p53, in cervical intraepithelial neoplasia and invasive squamous cell carcinoma of the uterine cervix
	666.	ATM or TP53 deletion is associated with high expression level of CD38 and TP53 deletion as a possible prognostic factor in Chinese patients with chronic lymphocytic leukemia
	667.	conclude that the effect of p53 codon 72 genotype on breast cancer survival is dependent on p53 gene status, the P/P variant is strongly associated with poor prognosis among patients with a wild-type p53 tumor
	668.	Rb antagonizes gankyrin to inhibit MDM2-mediate p53 ubiquitination in cancer cells and suggest that the status of both p53 and Rb is important for efficacy of cancer chemotherapy.
	669.	acute loss of p53 in normal HKc induces EGFR expression by a mechanism that involves YY1 and Sp1 and does not require p53 binding to the EGFR promoter
	670.	nuclear extracts immunodepleted of p53 or nuclear extracts of p53-null cells were unable to excise UVC-induced DNA adducts, and introduction of p53 by transfection restored the excision activity
	671.	This study provides the first evidence that p53 is involved in the regulation of EBV lytic cycle initiation.
	672.	A significant association was found in Dukes' B stage colorectal cancer patients between the GSTM1 and p53 gene variants and survival.
	673.	Notch-1 upregulates EGFR expression and also demonstrate Notch-1 regulation of p53 in gliomas.
	674.	p53 single-nucleotide polymorphism is associated with the early development of hepatocellular carcinoma in Korean patients with chronic HBV infection.
	675.	A possible correlation between overexpression of p53, proliferating cell nuclear antigen (PCNA), and c-erbB-2, and the clinicopathologic features of laryngeal squamous cell carcinoma, was investigated.
	676.	A novel isochroman derivative inhibited apoptosis in vascular endothelial cells through depressing the levels of integrin beta4 and TP53.
	677.	K-ras and p53 genes are altered in Tamoxifen-associated endometrial carcinoma
	678.	In the absence of p53 function, the resulting derepressed CD44 expression is essential for the growth and tumor-initiating ability of highly tumorigenic mammary epithelial cells.
	679.	Oral verrucous carcinoma tumorigenesis may involve the inactivation of p53, which is associated with HPV infection.
	680.	was no difference in the expression of EGFR, p185(erbB-2) or Bcl-2, or in nuclear accumulation of p53 in these IDC from pre- vs. post-menopausal women.
	681.	Data identified TAF3 as an evolutionarily conserved negative regulator of p53 transcription activation function.
	682.	data clearly show neither association between SNP309 and cancer risk, nor the responsibility of G allele for increased MDM2 or decreased of p53 protein levels in human primary breast tumors.
	683.	All of the E6 genes from different HPV types displayed similar abilities to mediate the degradation of both p53 and MAGI-3
	684.	p53 has a role in preventing centrosome amplification, ERalpha phenotypic heterogeneity and metastasis in breast cancer
	685.	Neither germline variants in p53 nor MDM2 SNP309 play an underlying role in the development of very early onset CRC
	686.	PKC epsilon mediates TRAIL resistance by Akt-mediated phosphorylation of Hdm2 resulting in suppression of p53 expression and downregulation of Bid in breast cancer cells
	687.	Inhibition of methylation in hnRNP K attenuated the recruitment of p53 to p21 promoter, and reduced p53 transcriptional activity.
	688.	the p53 gene does not appear to play a major role in pheochromocytoma tumorigenesis.
	689.	p53 of stromal fibroblasts affects the response of a tumour against chemotherapy by inducting senescence in the fibroblasts which results in the production of growth factors acting onto the cancer cells by paracrine mechanisms.
	690.	These results suggest that a p53-dependent cell cycle checkpoint monitors changes of cellular NS levels via the impediment of MDM2 function.
	691.	Signaling of DNA damage is not sufficient to induce p53 response: (re)activation of wt p53 protein strongly depends on cellular context.
	692.	DNA damage combined with hypoxia modulated both the intensity of the p53 response and the composition of downstream target genes.
	693.	frequency of TP53 mutations using purified tumor DNA from ovarian serous carcinomas was 80.3%, which is much higher than reported. We found that TP53 is not directly involved in development of drug resistance in high-grade ovarian serous carcinomas.
	694.	High zinc status in normal bronchial epithelial cells upregulates p53 expression which in turn elevates p21, inducing G2/M blockage.
	695.	Intrinsic radiosensitivity of 39 human tumor cell lines segregate into distinct genotype-dependent radiosensitivity groups that associate with mutATM, wtTP53, mutTP53, and an unidentified factor in some glioblastoma cells.
	696.	the functional role of the intrinsic activation of p53 during Mk differentiation is to control polyploidization and the transition to endomitosis by impeding cell cycling and promoting apoptosis.
	697.	disruption of the spindle-assembly checkpoint does not directly influence p53 activation, but the shortening of the mitotic arrest allows cyclin E-CDK2 to be activated before the accumulation of p21(CIP1/WAF1).
	698.	Thus, elevated levels of CCN3 protein regulated by p53 might influence cell adhesion.
	699.	Downregulation of caspase 2 levels by p53 may help to determine cell fate by preventing cell death when unnecessary.
	700.	Results correlate P53 status and mutation site/type with nuclear protein accumulation, clinicopathologic variables and data on K-ras mutations and high-level microsatellite instability.
	701.	TP53 may have a direct, allele specific, role in 5-FU mediated response.
	702.	Genetically programmed cell death is related to the p27, cathepsin and survivin pathways in Fuchs' dystrophy and to the p21 and p27 pathways in pseudophakic bullous keratopathy.
	703.	p53 promotes theaflavin-induced apoptosis in a transcription-dependent manner through mitochondrial death cascade.
	704.	autophagy is regulated by cytoplasmic p53
	705.	p53-Driven apoptosis limits centrosome amplification and genomic instability downstream of NPM1 phosphorylation
	706.	Data show that the elimination of the salt bridge and the inversion of the flexibility of L1 and L3 are directly or indirectly responsible for deactivating the tumor suppressor p53.
	707.	functional interaction of NEDL1 with p53 might contribute to the induction of apoptosis in cancerous cells bearing wild-type p53.
	708.	following DNA damage, PML facilitates Thr18 phosphorylation by recruiting p53 and CK1 into PML nuclear bodies, thereby protecting p53 from inhibition by Mdm2, leading to p53 activation.
	709.	The demonstration that p53 binds directly to the PIK3CA promoter and inhibits its activity identifies a novel mechanism whereby these two mediators regulate cellular functions.
	710.	These findings indicate that p53 is a transcriptional regulator of DUSP1 in stress responses.
	711.	Results suggest that genetic analysis of TP53 can select patients at high risk of bladder tumour progression that should be followed closely and may benefit from early radical surgical procedures.
	712.	data suggest that UVB-induced, stress-induced premature senescence in skin fibroblasts plays an important role in p53-related apoptosis resistance and tumor suppression activity
	713.	Results suggest that the parthenolide-induced apoptosis of A549 cells is due to the direct suppression of NF-kappaB activity in a p53- and hsp72-independent manner based on NF-kappaB signaling.
	714.	New triterpenoid from Panax ginseng exhibits cytotoxicity through p53 and the caspase signaling pathway in the HepG2 cell line.
	715.	stabilization of MDMX by Akt may be an alternative mechanism by which Akt up-regulates MDM2 protein levels and exerts its oncogenic effects on p53 in tumor cells
	716.	TP53 is not a major contributor to BRCA1 and BRCA2 mutation-negative breast and/or ovarian cancer families of French Canadian descent
	717.	The Pro allele in the codon 72 of TP53 was observed in 5/9 glioma tumors.
	718.	TERT association with TP53 mutations indicates that TERT activity is downregulated by functional p53 protein in breast tumors.
	719.	TP53 Arg72Pro polymorphism, but not p73 G4C14>A4TA4 and p21 Ser31Arg, contribute to risk of cutaneous melanoma
	720.	Increased TP53 expression was associated with invasive adenocarcinoma of the prostate
	721.	Different mutant/wild-type p53 combinations cause a spectrum of increased invasive potential in nonmalignant immortalized human mammary epithelial cells
	722.	Induced the transition from cardiac hypertrophy to heart failure through the suppression of hypoxia inducible factor-1(HIF-1), which regulates angiogenesis in the hypertrophied heart and promotes apoptosis.
	723.	Overexpression of p53 is associated with several different clinicopathological features of ovarian carcinoma including parameters of stage, tumor grade and prognosis.
	724.	A signaling cascade for the regulation of p53 in response to ionizing radiation was proposed that involves activation of DNA-PK and Akt/PKB and inactivation of GSK-3 and Mdm2.
	725.	HIPK2 has a critical role in maintaining the transactivation activity of wtp53; low expression of HIPK2 may impair the p53 function in tumors harboring wtp53
	726.	although p53 mutation is relatively rare, the type and distribution of mutations in low-grade B-cell malignancy patients does not differ significantly from other forms of cancer
	727.	results support the notion that acetaldehyde plays a role in TP53 mutations in esophageal cancers
	728.	p14ARF hypermethylation is common but INK4a-ARF locus or p53 mutations are rare in Merkel cell carcinoma.
	729.	p53Arg homozygosity is associated with the development of sporadic colorectal adenocarcinoma, in the Greek-Caucasian population studied
	730.	Data suggest that p53 pulses result from repeated initiation by ATM, which is reactivated by persistent DNA damage.
	731.	study investigated the correlation of p53 abnormalities in 15 patients with pulmonary large cell carcinomas; 5/15 expressed p53 and none had mutant p53 sequences; there was a negative survival correlation with positive p53 immunostaining (P = 0.05)
	732.	Tacrolimus ointment neither blocks ultraviolet B nor affects expression of thymine dimers and p53 in human skin.
	733.	p53/47 controls the folding, the oligomerisation and the post-translational modification of p53 complexes and that it diversifies p53 properties in a cell stress-dependent fashion.
	734.	CSN5 is a pivotal regulator for both p53 and MDM2
	735.	the ability to promote Lys(63)-mediated polyubiquitination of COMMD1 is a novel property of ARF independent of p53
	736.	Compared to PAI-1 protein levels, Chalkley counts and MIB-1, HER2+ and mutations of TP53 were the strongest independent markers of poor prognosis irrespective of nodal statusin breast cancer.
	737.	p53 was not associated with survival after radiotherapy in high-risk breast cancer, but BCL2 might be.
	738.	The clinical outcome for breast cancer patients is significantly different for different TP53 mutation types.
	739.	B7-H4 was expressed more often in pancreatic ductal carcinoma than was p53.
	740.	the expression manner of PTEN, beta-catenin, and p53 immunocytochemistry was observed in the normal endometrium (proliferative, secretory, and atrophic, and endometrial glandular and stromal breakdown[beta-catenin]
	741.	the expression manner of PTEN, beta-catenin, and p53 immunocytochemistry was observed in the normal endometrium (proliferative, secretory, and atrophic, and endometrial glandular and stromal breakdown
	742.	results support Killin as a missing link between p53 activation and S phase checkpoint control designed to eliminate replicating precancerous cells, should they escape G(1) blockade mediated by p21.
	743.	Lentiviral delivery of small hairpin RNA targeting Tthymidylate kinase in combination with a low dose of doxorubicin as a new approach to kill colon cancer cells regardless of p53 status.
	744.	p53-mediated mir34a, mir34b, and mir34c up-regulation and ING2 down-regulation may be involved in the senescence pathway.
	745.	Study identifies p53 acetylation as an indispensable event that destabilizes the p53-Mdm2 interaction and enables the p53-mediated stress response.
	746.	determined the average ensemble structure of the intrinsically disordered N-terminal transactivation domain in both the full-length tetrameric p53 protein and in its complex with a specific DNA response element
	747.	Conclude that the Ki-67 and p53 labeling indices are useful additional tools in discriminating atypical from benign or anaplastic meningiomas.
	748.	The results presented in this report emphasized flow cytometry as an important tool for the fast evaluation of p53 protein expression levels as bioindicator of individual exposure to acute ionizing radiation.
	749.	Describe a novel p53 rescue compound that induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis.
	750.	MDM2 SNP309, alone or in combination with TP53 R72P, was not associated with oligodendroglial tumors.
	751.	TP53 Pro47Ser and Arg72Pro SNPs are not involved either in susceptibility to developing gliomas or in patient survival
	752.	Combined increased p53 and reduced membranous beta-catenin protein expression indicated a very poor prognosis in patients with esophageal squamous cell carcinoma.
	753.	TGF-beta(1) production in carcinoma cells was associated with doxorubicine-mediated p53 expression in MCF-7 cells or high basal level of p53 in T47D cells.
	754.	DLBCL in pre-menopausal women of central European Caucasian ethnicity was not associated with SNP309 G. Neither SNP309 nor SNP72 seem to be correlated with age of onset, diagnosis, or survival of diffuse large B-cell non-Hodgin lymphoma patients.
	755.	Abrogation of G2 checkpoint by Geldanamycin may play a central role in sensitizing p53-negative tumor cells to DNA-damaging and decatenation-inhibiting agents.
	756.	mutated over wild-type P53 mRNA exists in glioblastoma cells with heterozygous mutations of this gene.
	757.	p53 family may play a role in the epithelial cell response to H pylori infection.
	758.	Tubal p53 signature merits serious consideration as an important early event in serous carcinogenesis in BRCA+ women.
	759.	in epithelial cells, some of the functions of p53 leading to cell-cycle arrest and apoptosis are restrained by HHV-6B infection, whereas other cellular defences, causing inhibition of virus transcription, are partially retained.
	760.	P53 mutations are associated with higher levels of Intratumoral T cells.
	761.	Flotillin 2 is a direct transcriptional target of the p53 family member genes in human cancer cells.
	762.	These results suggested that Annexin A2 may play roles in p53 induced apoptosis and it is also involved in regulation of cell proliferation.
	763.	UNC5H4 amplifies p53-dependent apoptotic response.
	764.	Microsatellite alterations, and p53 tumor mutations are associated with non-small cell lung cancer patients
	765.	The data show that immunostaining for p53 and HbF as well as karyotype analysis are useful for the differential diagnosis of myelodysplastic syndrome and aplastic anemia.
	766.	data indicate that in early and advanced gastric tumors, p53 and bcl-2 protein accumulation is more intense in gastric mucosa adjacent to advanced tumors and p53 immunoreactivity peaks in advanced carcinomas
	767.	an important role for the DNA damage response mediated by ATR-Chk2 in p53 activation and renal cell apoptosis during cisplatin nephrotoxicity.
	768.	The DNA binding domains of p73 exhibited enhanced thermodynamic stability relative to the p53 DBD, and the p73 surface is less complementary for DNA binding, which may account for the differences in affinity and specificity for p53 REs.
	769.	CARF exerts a vital control on the p53-HDM2-p21WAF1 pathway that is frequently altered in cancer cells.
	770.	lymphocytes showed repeatedly an extensive proportion of TP53 mutated cells, harboring various TP53 mutations, mostly single-point, in individual cells. The mutation targeting exhibited characteristic traits of the somatic hypermutation process
	771.	cigarette smoking may influence breast cancer risk through interaction with p53.
	772.	Superior outcome of t(8;21) acute myeloid leukemia patients is partly due to an activated p53 pathway, and that loss of the p53 response pathway is associated with disease progression.
	773.	Can physically interact with the transcription elongation complex and influence transcription elongation.
	774.	In the group of patients < or =53 yrs and with TP53(-) tumors platinum-based therapy is possibly equally efficient.
	775.	that the recruitment of YB1, PURalpha, and H1.2 to the p53 target gene Bax is required for repression of p53-induced transcription.
	776.	The p53 target sequences possessing the inverted repeat symmetry were shown to form a cruciform structure in sufficiently negative supercoiled DNA.
	777.	Investigation of the mechanism underlying p53 reactivation in hepatitis B virus X-protein-expressing cells.
	778.	The p53 Pro72 homozygous non-small cell lung cancer patients often presented high-grade tumours and had significantly poorer survival rates than patients with R72 homozygotes or heterozygotes.
	779.	p53beta and Delta40p53 are expressed in melanoma and this may have important implications for understanding resistance of melanoma to DNA-damaging chemotherapy.
	780.	p53 and p16(INK4A) are promising candidates for the pulmonary molecular screening of heavy smokers healthy individuals.
	781.	Mutation of p53 gene is probably one of the most important factors to initiate the endometrial serous carcinogenesis.
	782.	p53 is activated by stimulation of mismatch repair in response to the misincorporation of deoxynucleotides into newly synthesized DNA, long before the lack of pyrimidine nucleoside triphosphates causes the rate of DNA synthesis to slow appreciably.
	783.	p53 and p73 repress a number of growth-related genes and that in many instances this repression may be through the induction of p21.
	784.	Detailed mapping of chromosome 17p deletions reveals HIC1 as a novel tumor suppressor gene candidate telomeric to TP53 in diffuse large B-cell lymphoma
	785.	Histone deacetylase inhibitors may overcome neuroblastoma drug resistance by restoring p53 tumour-repressor function via its hyper-acetylation and nuclear migration.
	786.	p53 positivity was significantly associated with higher risk of disease-specific and recurrence-free mortality in HPV-HR head and neck neoplasms.
	787.	the role of triptolide as a sensitizer to TRAIL-induced apoptosis in part by independent modulation of XIAP expression and p53 signaling.
	788.	E6-AP not only enhances the degradation of p53 but also regulates the neuronal cell growth.
	789.	Identification of anomalous, detectable conformational state of p53 from sporadic Alzheimer's disease (AD) patients allows differentiation of fibroblasts from those of age-matched non-AD subjects and suggests a role for conformationally altered p53 in AD.
	790.	patients with chronic lymphocytic leukemia (CLL) we have identified a novel p53 splicing variant, lacking the whole coding sequence of exon 6.
	791.	Aberrations could be considered markers responsible for the development of odontogenic lesions.
	792.	Results describe the interrelationship between H pylori and Epstein-Barr virus infection in gastric carcinogenesis, focusing on p53 mutation and c-Myc, Bcl-2 and Bax expression.
	793.	The distinction between various populations may be because of differences in racial composition and/or exposure to distinct environmental factors that have a different impact on systemic lupus erythematosus incidence along with the Argp53Pro genotype.
	794.	Overexpression of p53 was associated with poor survival in gallbladder carcinomas.
	795.	Stimulation of KLF6 expression by IGF-I in a p53-dependent manner may constitute a novel mechanism of action of IGF-I, with implications in normal cell cycle progression and cancer biology.
	796.	A novel cis-element in the 5' coding region of p53 mRNA and its interaction with heterogeneous nuclear ribonucleoprotein (hnRNP)C1/C2, is described.
	797.	Defective p53 signaling in p53 wild-type tumors attenuates p21waf1 induction and cyclin B repression rendering them sensitive to Chk1 inhibitors that abrogate DNA damage-induced S and G2 arrest.
	798.	quercetin stabilized p53 at both the mRNA and protein levels to reactivate p53-dependent cell cycle arrest and apoptosis in HepG2 cells
	799.	p16(INK4a), p21(WAF1/CIP1), p27(KIP1), and p53 are expressed in human corneal endothelial cells despite donor ages.
	800.	p53 expression and certain apoptosis markers correlate with survival in thymic neuroendocrine tumors.
	801.	The role of p53 in DNA damage-mediated cytotoxicity overrides its ability to regulate nucleotide excision repair in human fibroblasts
	802.	p53 mutations and microsatellite instability differ in patients with gallbladder carcinoma between two distinct high-incidence areas
	803.	significantly higher levels of HCV RNA replication and viral protein expression in Huh7 cells when their p53 expressions were knocked down; p53 found to directly interact with IRF9
	804.	Monomeric but not trimeric clathrin heavy chain regulates p53-mediated transcription.
	805.	Upregulation of MDR1 by DeltaNp73alpha is mediated by interaction with p53 at the MDR1 promoter.
	806.	in endometrial carcinoma p53 overexpression was directly associated with unfavorable clinicopathologic factors: advanced stage, histologic subtype, advanced patient age and nodal metastasis
	807.	P53 expression in H1299 cells reduced the sub-G1 fraction. p53 enhanced the repair of UV-induced DNA damage. Human p53, unlike CHO-K1 p53, may play active roles in both UV-induced apoptosis & repair.
	808.	p53 codon 72 variant genotypes modify the risk of human papiloma virus 16-associated SCCOP and may be markers of genetic susceptibility to HPV16-associated squamous cell carcinoma of the mouth and pharynx.
	809.	Both germ line and somatic alterations of the TP53 pathway influence incidence and survival of ovarian carcinoma.
	810.	Required for the elimination of cells with aberrant CD43 expression.
	811.	The specific binding of the C-terminal acidic domain (AC-D) of the human TFIIEalpha subunit to the pleckstrin homology domain (PH-D) of the human TFIIH p62 subunit is demonstrated.
	812.	There is no any association of polymorphous marker C(-594)CC of TP53 gene with DPN in Russian patients with type 1 diabetes mellitus living in Moscow.
	813.	optimal binding of STAGA to p53 involves interactions of STAGA subunits TAF9, GCN5, and ADA2b, respectively
	814.	CARPs together with MDM2 enhance p53 degradation, thereby inhibiting p53-mediated cell death.
	815.	p53 mutation spectra and differences with histology in lung cancers.
	816.	The proper combination of IFNalpha and conventional chemotherapeutic agents may be a rational strategy for the treatment of human osteosarcoma with functional p53.
	817.	Together our results show that hDDA3 is a p53- and DNA-damage down-regulated target that exhibits oncogenic characteristics.
	818.	Smo mutants augment p53 binding to the E3 ubiquitin-protein ligase Mdm2 and promote p53 ubiquitination.
	819.	the Hes6-CBP complex in PML-NB may influence the proliferation of cells via p53-dependent and -independent pathways.
	820.	identified the binding site of the p53 and FAK interaction and demonstrated that mutating this site and targeting the site with peptides affects p53 functioning and viability in the cells.
	821.	This review emphasizes various mechanisms activated by p53 signalling that can confer protection to cells with damaged DNA in the context of p53's pro-apoptotic and pro-survival activities.
	822.	Patients with pathologically N0 disease and p53 gene mutation must be carefully monitored for local recurrence or distant metastasis.
	823.	enhanced phosphorylation of p38 and p53 (ser15) in ZS cells was normalized after suppression of Gadd45 by siRNA
	824.	PUMA exerts a negative feedback on p53 and p21, leading to p21-dependent growth suppressive and survival changes.
	825.	These findings indicate that R337H may be a low penetrance mutant which predisposes to multiple cancers
	826.	[Review] Besides its ability to promote apoptosis through transcription dependent mechanisms, p53 may also be able to activate apoptosis independent of transcriptional regulation.
	827.	cytosolic p53 may participate in the regulation of clathrin-mediated endocytosis to control the correct signaling from EGFR
	828.	Deletion of the 9p21 locus inhibits p53 protein; studies of the ARF-MDM2-P53 pathway link survival and chemoresistance in patients with abnormalities in 17p and 9p
	829.	PTEN acquires unexpected properties by enhancing gain-of-function mutant p53 (mut-p53) protein levels. PTEN restoration to cells harboring mut-p53 leads to induction of G(1)-S cell cycle progression and cell proliferation and to inhibition of cell death.
	830.	Data suggest that p53 regulates cellular responses to environmental carcinogen benzo[a]pyrene-7,8-diol-9,10-epoxide in human lung cancer cells.
	831.	Results suggest that the roles of p53 and nucleotide excision repair in the recovery from UV-induced replication are separable and DDB2-independent.
	832.	Results show that p14ARF regulates E2F-1 ubiquitination and degradation via a p53-dependent mechanism.
	833.	ERK and JNK MAPK/Elk-1/Egr-1 signal cascade is required for p53-independent transcriptional activation of p21(Waf1/Cip1) in response to curcumin in U-87MG human glioblastoma cells
	834.	Therefore, our results suggest that the interaction between Sirt2 and 14-3-3 beta/gamma is a novel mechanism for the negative regulation of p53 beside the well-characterized Mdm2-mediated repression.
	835.	The prevalence of MDM2 gene amplifications and single nucleotide polymorphism 309 in 284 colorectal tumors in relation to TP53 mutational status and genomic instability, is analyzed.
	836.	The morphology and cell cycle proteins immunoexpression of the novel probable preinvasive lesion - bronchiolar columnar cell dysplasia (BCCD), is decribed.
	837.	These findings suggest that inhibition of the class I PI3K signaling pathway is a potential strategy for managing gastric cancers.
	838.	A correlation of p53 expression with AI and PI was found in pilocytic astrocytoma but not in glioblastoma.
	839.	High p53 expression level with low MDM2 and p14 ARF levels may be the characteristic features of low differentiated endometrial carcinoma
	840.	Suggest beta-catenin deregulation is involved in sporadic hepatoblastoma and also suggests that mismatch repair defects and p53 mutations contribute to this rare liver cancer.
	841.	the potential use of R-Roscovitine as a bitargeted anticancer drug that functions by simultaneously causing p53 activation and NF-kappaB suppression.
	842.	DEC1 is induced by the p53 family and DNA damage in a p53-dependent manner. p53 family proteins bind to, and activate, the promoter of the DEC1 gene.
	843.	the functions of p53 play substantial roles in many other pathologies as well as in the aging process [review]
	844.	p53-mediated apoptosis occurs by a PIDD- and caspase 2-dependent mechanism, and p53's full transcriptional regulatory functions may be required only for events that are downstream of cytochrome c release
	845.	results suggest that gene-smoking and gene-gene interactions may impact the prevalence of p53 mutations in breast tumors
	846.	p53 mutations at CpG dinucleotides provide further evidence for a molecular link between chronic inflammation and esophageal malignancy.
	847.	p53 codon-249 mutations are associated with X-ray repair cross complementing protein 1 polymorphism Arg399Gln among the Guangxi population of China.
	848.	among p53 Arg/Arg carriers, HPV infection, smoking, and drinking might further increase the risk of esophageal squamous cell carcinoma development
	849.	These data suggest a more complex role for TRIM22 during T lymphocyte activation than merely as an antiproliferative factor.
	850.	mutant p53 loses its ability to suppress DNMT1 expression, and thus enhances methylation levels of the p16 ( ink4A ) promoter and subsequently down-regulates p16(ink4A )protein.
	851.	compromise of either p53 or Rb pathways during melanocyte transformation leads to up-regulation of survivin expression in melanoma
	852.	p53 homolog, p63, may participate in governing global repair instead of p53 in keratinocytes
	853.	circulating anti-p53 antibodies (anti-p53Ab) in sera of cancer patients may have a role in disease progression
	854.	the presence of both HPV infection and TP53 mutations may define a particular group of tumors with a more aggressive phenotype in advanced oral squamous cell carcinoma
	855.	Changes in p53 expression seen in urothelial and sinonasal inverted papillomas suggest they may share common evolution.
	856.	p53 is required for the efficient removal of cross links in human cells; cytotoxic cross links persist in p53-deficient cells.
	857.	p53 function is not sufficient to suppress glucose uptake in cells and tumors that could theoretically support aerobic glycolysis.
	858.	The proliferative activity and p53 overexpression increased with the dedifferentiation of tranitional cell bladder carcinoma.
	859.	although HPV16 (human papiloma virus 16) and mutated p53 may coexist in a subset of squamous cell carcinomas of the head and neck, HPV16 and disruptive p53 mutations seem to be nonoverlapping events
	860.	SS18-SSX1 can negatively regulate p53 tumor-suppressive function by increasing the stability of its negative regulator HDM2.
	861.	These results indicate that in thyroid cancer cells, TAp73alpha is able to increase p53 protein level and function by interfering with Mdm2-mediated p53 degradation.
	862.	ability of p53 to down-modulate osteoprotegerin production by endothelial cells may be an additional important mechanism
	863.	homeodomain interacting protein kinase 4 phosphorylates p53 at serine 9 is important for p53 mediated transcriptional repression.
	864.	p63 exhibits several transcriptional and stress-response properties similar to those of p53
	865.	germ line and somatic alterations of the p53 pathway influence the incidence and survival of ovarian carcinoma
	866.	in a Portuguese population, the p53 R72P polymorphism is not associated with an increased susceptibility to squamous intraepithelial lesions or cervical cancer development
	867.	that Skp2 controls p300-p53 signaling pathways in cancer cells, making Skp2 a potential molecular target for cancer therapy.
	868.	defects in the p53 regulatory cascade do not appear operational in this leukemia
	869.	P53 immunohistochemical profile may be useful in detecting colorectal adenomas with a malignant potential.
	870.	During fludarabine treatment of Raji and MEC1 cells, proteolytic derivatives of p53 with MW of ~47 and ~40 kDa appeared. There were 8 phosphorylated forms. These could play crucial roles in apoptosis induction.
	871.	These findings suggest novel Cdk1/cyclin A phosphorylation sites, which appear to be associated with p53-independent cell death following etoposide treatment.
	872.	Study shows that p53 over expression in Crohn's Disease is associated with dysplasia that may progress to a higher grade of neoplasia over time.
	873.	p53 mutation was exhibited in pulmonary sclerosing haemangioma. The mutation rate in polygonal cells was higher than that in surface cuboidal cells
	874.	p53 is of limited value only, being largely overshadowed by the prognostic capability of FIGO stage and extent of residual disease.
	875.	A high proportion of familial microsatellite instability cases and a lower incidence of TP53 mutations were found in Saudi colorectal carcinoma.
	876.	The increase of cell membranous phosphatidylcholines containing unsaturated fatty acid residues induces phosphorylation of p53 through activation of ATR.
	877.	p53 codon 72 and intron 3 polymorphisms are associated with non-small cell lung cancer
	878.	These studies suggest that PARC-interacting peptides are promising candidates for the enhancement of p53-dependent apoptosis in tumors with wt cytoplasmic p53.
	879.	Our results indicate that nicotinamide treatment attenuates p21WAF1 expression through Sp1 downregulation, and suggest a possible involvement of nicotinamide metabolism in cellular gene expression.
	880.	a network involving signal coactivation of NF-kappaB and STAT3, differentially modified by p53 inactivation or mutation, promotes altered BAX/BCL-XL expression and cell survival in HNSCC.
	881.	Distinct rare missense mutations of the TP53 gene were detected in Capi1 (codon 312) and Capi3 (codon 181); the codon 181 mutation is consistent with a previously reported similar finding in a small series of CUP specimens.
	882.	The data support that the frequencies and patterns of somatic mutation of the p53 genes in colorectal cancer are variable among populations.
	883.	P53 mediated regulation of metallothionein transcription in breast cancer cells is reported.
	884.	P53 Arg72Pro and MDM2 T309G polymorphisms contribute to the risk of developing stomach cancer.
	885.	Current study showed p53 was associated with induction of apoptosis and cell proliferation in early stage gastric cancers, but not in the subserosa of advanced gastric cancer.
	886.	An animo acid substituition is a risk factor for breast cancer.
	887.	Risk for head and neck squamous cell carcinoma may be assocated with single-nucleotide polymorphism in the promoter region.
	888.	Isoleucine 31-type p53 may be partly involved in familial gastric cancer because of its low transcriptional activity and low cell proliferation suppressing activity.
	889.	Some mutant forms can be reactivated by amifostine, mostly in the DNA-binding domain.
	890.	TP53 mutations reduce the prostate cancer (PCa)-free survival time in patients with needle biopsy of the prostate and primary benign diagnosis; Exon 6 mutations enhance the risk of being affected by PCa 32-fold
	891.	a combined expression of survivin and p53 was associated with an increased risk of tumor local progression.
	892.	Observational study and meta-analysis of gene-disease association. (HuGE Navigator)
	893.	Observational study of gene-gene interaction, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)
	894.	Observational study of genotype prevalence, gene-disease association, and gene-environment interaction. (HuGE Navigator)
	895.	Observational study of genotype prevalence and gene-disease association. (HuGE Navigator)
	896.	Observational study of genetic testing. (HuGE Navigator)
	897.	Observational study of gene-environment interaction. (HuGE Navigator)
	898.	Observational study of genotype prevalence and gene-environment interaction. (HuGE Navigator)
	899.	Observational study of genotype prevalence and genetic testing. (HuGE Navigator)
	900.	Observational study of gene-disease association and pharmacogenomic / toxicogenomic. (HuGE Navigator)
	901.	Observational study of gene-disease association, gene-gene interaction, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)
	902.	Meta-analysis of gene-disease association. (HuGE Navigator)
	903.	Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)
	904.	Observational study of gene-environment interaction and pharmacogenomic / toxicogenomic. (HuGE Navigator)
	905.	Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator)
	906.	Observational study of gene-disease association, gene-gene interaction, and gene-environment interaction. (HuGE Navigator)
	907.	Observational study of genotype prevalence. (HuGE Navigator)
	908.	Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator)
	909.	Observational study of gene-disease association. (HuGE Navigator)
	910.	Expression of p53 expression was weak or not detected in dental follicles with reduced and stratified squamous epithelium
	911.	p53 activity is differentially regulated by Brm- and Brg1-containing SWI/SNF chromatin remodeling complexes
	912.	HHV-6B induces p53 Ser392 phosphorylation by an atypical pathway independent of casein kinase 2 protein and p38 kinases.
	913.	Examine interaction between TP53 and the C-terminal fragment of p53 (M protein).
	914.	Findings suggest TP53 PIN3 Ins16bp polymorphism as a real risk modifier in breast cancer disease, either in sporadic and familial breast cancer. Furthermore, both TP53 polymorphisms are associated with higher incidence of lymph node metastases.
	915.	These data provide evidence that there is a novel signaling pathway from Dishevelled to p53.
	916.	In this first assessment of the role of TP53 Arg72Pro polymorphism in a large series of Portuguese glioma tumors, no association was observed with glioma susceptibility or overall survival, except for patients submitted to adjuvant therapy.
	917.	Genetic alterations of the p53 tumor suppressor gene were seen in a mixed serous carcinoma of the endometrium.
	918.	initially p53-negative tumors and initially p63-positive tumors that retain this labeling pattern m

Table Of Contents

Links

Entrez Gene Info

General info

Related sites

Feedback

Subscriptions

Recent Activity

1: TP53 tumor protein p53 [ Homo sapiens ]

[Top][Help]Summary

[Top][Help]Genomic regions, transcripts, and products

[Top][Help]Bibliography

Related Articles in PubMed

GeneRIFs: Gene References Into Function What's a GeneRIF?